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Abstract
The aim of rational drug design is to develop small molecules using a quantitative approach to
optimize affinity. This should enhance the development of chemical compounds that would
specifically, selectively, reversibly, and with high affinity interact with a target protein. It is not
yet possible to develop such compounds using computational (i.e., in silico) approach and
instead the lead molecules are discovered in high-throughput screening searches of large com-
pound libraries. The main reason why in silico methods are not capable to deliver is our poor
understanding of the compound structure–thermodynamics and structure–kinetics correla-
tions. There is a need for databases of intrinsic binding parameters (e.g., the change upon
binding in standard Gibbs energy (ΔGint), enthalpy (ΔHint), entropy (ΔSint), volume
(ΔVintr), heat capacity (ΔCp,int), association rate (ka,int), and dissociation rate (kd,int)) between
a series of closely related proteins and a chemically diverse, but pharmacophoric group-guided
library of compounds together with the co-crystal structures that could help explain the struc-
ture–energetics correlations and rationally design novel compounds. Assembly of these data
will facilitate attempts to provide correlations and train data for modeling of compound bind-
ing. Here, we report large datasets of the intrinsic thermodynamic and kinetic data including
over 400 primary sulfonamide compound binding to a family of 12 catalytically active human
carbonic anhydrases (CA). Thermodynamic parameters have been determined by the fluores-
cent thermal shift assay, isothermal titration calorimetry, and by the stopped-flow assay of the
inhibition of enzymatic activity. Kinetic measurements were performed using surface plasmon
resonance. Intrinsic thermodynamic and kinetic parameters of binding were determined by
dissecting the binding-linked protonation reactions of the protein and sulfonamide. The com-
pound structure–thermodynamics and kinetics correlations reported here helped to discover
compounds that exhibited picomolar affinities, hour-long residence times, and million-fold
selectivities over non-target CA isoforms. Drug-lead compounds are suggested for anticancer
target CA IX and CA XII, antiglaucoma CA IV, antiobesity CA VA and CA VB, and other
isoforms. Together with 85 X-ray crystallographic structures of 60 compounds bound to six
CA isoforms, the database should be of help to continue developing the principles of rational
target-based drug design.
Abbreviations
ANS, 1,8-anilinonaphthalene sulfonate; AZM, acetazolamide (also commonly abbreviated as
AZA, AAZ, ACTAZ); CA, carbonic anhydrase; DSC, differential scanning calorimetry; DSF,
differential scanning fluorimetry; EZA, ethoxzolamide; FPSA, fluorescent (fluorescence-based)
pressure shift assay, PressureFluor; FTSA, fluorescent (fluorescence-based) thermal shift assay,
alternatively termed ThermoFluor or differential scanning fluorimetry, DSF; int, intrinsic; ITC,
isothermal titration calorimetry; MZM, methazolamide (also commonly abbreviated as
METHZ); NA, not available (attempted but could not be conclusively determined); ND, not
determined; obs, observed; SFA, stopped-flow assay; SPR, surface plasmon resonance;
SULFA, sulfanilamide; TFS, trifluoromethanesulfonamide (also commonly abbreviated as
TFMSA).
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Variables
Δβ, isothermal compressibility; ΔCp, constant pressure heat capac-
ity; ΔG, standard Gibbs energy of binding (equivalent to ΔG°);
ΔGint, intrinsic standard Gibbs energy change on binding;
ΔGobs, observed standard Gibbs energy change on binding;
ΔGpr,CA, standard Gibbs energy change on protonation of CA–
ZnII-bound hydroxide; ΔGpr,SA, standard Gibbs energy change
on protonation of deprotonated sulfonamide amino group; ΔH,
standard enthalpy change on binding (equivalent to ΔH°);
ΔHint, intrinsic standard enthalpy change on binding; ΔHobs,
observed standard enthalpy change on binding; ΔHpr,buf, standard
enthalpy change on buffer protonation; ΔHpr,CA, standard
enthalpy change on CA–ZnII-bound hydroxide protonation;
ΔHpr,SA, standard enthalpy change on protonation of deproto-
nated sulfonamide amino group; IC50, inhibitor concentration
that inhibits 50% of enzymatic activity; ka, association rate cons-
tant; ka,int, intrinsic association rate constant; Kb, equilibrium
binding constant; Kb,int, intrinsic equilibrium binding constant;
Kb,obs, observed equilibrium binding constant; Kd, equilibrium
dissociation constant; KD, equilibrium dissociation constant
(used in kinetics (SPR), equivalent to Kd); Kd,int, intrinsic equilib-
rium dissociation constant; Kd,obs, observed equilibrium dissocia-
tion constant; Kd, dissociation rate constant; Kd,int, intrinsic
dissociation rate constant; Ki, inhibition of enzymatic activity
constant; KM, Michaelis constant of an enzyme; pKa, negative log-
arithm of the dissociation constant of acid protons; pKa,CA, neg-
ative logarithm of the dissociation constant of acid protons
from CA–ZnII-bound water molecule; pKa,SA, negative logarithm
of the dissociation constant of acid protons from the protonated
sulfonamide amino group; Pt, total protein concentration; ΔS,
standard entropy change on binding (equivalent to ΔS°); ΔSpr,
CA, standard entropy change on protonation of CA–Zn
II-bound
hydroxide; ΔSpr,SA, standard entropy change of protonation of
deprotonated sulfonamide amino group; Tm, melting (unfolding,
denaturation) temperature of a protein; ΔV, the standard change
on binding of the volume of the protein–solvent–ligand system.
Introduction
The quantification of binding of low molecular weight chemical
compounds to proteins is a field of great importance in biomed-
ical sciences, especially in drug design. It has been proposed that
the optimization of the thermodynamic and kinetic parameters of
ligand binding to proteins should lead to compounds with
improved interaction characteristics and increased possibilities
to become drugs. Despite great efforts, it has become increasingly
clear recently that it is difficult to correlate small changes in the
thermodynamic parameters of binding with the structure of the
chemical compound. As suggested by Krimmer and Klebe
(2015), such correlations usually only work for closely related
compounds. The limited extent of correlation is exemplified by
enthalpy changes upon binding which are strongly influenced
by solute effects and/or structural flexibility (Geschwindner
et al., 2015). There are at least four types of correlations that
are of interest here for drug design, namely, the correlations
between compound chemical structure and it’s protein-binding
thermodynamic and kinetic parameters, and the correlations
between the crystallographic structure of the compound-protein
complex and it’s binding thermodynamic and kinetic parameters.
It is not yet possible to use computational methods to design
chemical compounds that interact with a particular binding site
on a target protein with a predictable affinity and other binding
parameters. There is a need of significantly larger experimental
data collections together with improved theoretical models that
would explain the correlations between both compound and pro-
tein structures and the binding energetics. In the direction
towards this goal, we see a need for the following experimental
datasets (databases) that need to be assembled or significantly
enlarged:
1. Large database of thermodynamic binding data of chemically
diverse, but also closely related, e.g., through a pharmaco-
phoric group, chemical compound library to a target protein;
2. Thermodynamic and kinetic databases of chemical compound
binding should be assembled for a series of closely related pro-
teins that possess similar structural fold and similar binding
sites (e.g., isoforms of the same enzyme, or mutants);
3. All thermodynamic parameters of binding that are possible to
measure should be accumulated, not only the affinity (ΔG), but
also the changes in the standard enthalpy (ΔH), entropy (ΔS),
heat capacity (ΔCp), and even volume (ΔV) and compressibility
(Δβ) upon binding;
4. Kinetic parameters of binding, the association rate (ka) and the
dissociation rate (kd, residence time, residence half period)
should be accumulated;
5. All the above-listed thermodynamic and kinetic parameters
should be intrinsic, where as many as possible of the undesired
contributions are subtracted (e.g., linked protonation, buffer,
salt, protein, and ligand conformation changes, etc.) to enable
the correlation of binding energies with the structures;
6. Structural characterization (e.g., by X-ray crystallography or
NMR) of the unliganded apo-protein and protein-compound
complexes, desirably for each binding reaction.
Significant efforts have been devoted to the assembly and cura-
tion of protein–ligand binding data and the following databases
have been assembled to address each of these goals.
The BindingDB (Gilson et al., 2016) (http://www.bindingdb.
org/bind/index.jsp) is a public web database of 1 427 022 mea-
sured binding affinities between 7026 potential target proteins
and 639 152 chemical compounds (as of January, 2018) that
were experimentally determined by various techniques including
enzyme inhibition and kinetics, isothermal titration calorimetry,
NMR, radioligand and competition, and numerous other assays.
The ChEMBL (Liu et al., 2015) (https://www.ebi.ac.uk/
chembl/) database contains chemical compound bioactivity data
against drug targets. The 2018-01-11 version contains 2 101 843
compounds, 14 675 320 activities, 1 302 147 assays, and 11 538
targets. This database of bioactive drug-like small molecules con-
tains compound chemical structures, calculated properties (e.g.,
log P, Molecular Weight, Lipinski parameters, etc.) and bioactiv-
ities (e.g., binding constants, pharmacology, and ADMET data).
Clinical progress data are currently being integrated into the
database.
The DrugBank (Wishart et al., 2006) (https://www.drugbank.
ca/) is a bioinformatics and cheminformatics resource that com-
bines drug chemical, pharmacological, and pharmaceutical data
with drug target sequence, structure, and pathway information.
The latest release of DrugBank (version 5.0.11, released
2017-12-20) contained 10 917 drug entries including 2352
FDA-approved small molecule drugs, 926 FDA-approved biotech
(protein/peptide) drugs, 108 nutraceuticals, and 5069 experimen-
tal drugs.
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PDBbind database (Liu et al., 2015) (http://www.pdbbind.org.
cn/) provides a comprehensive collection of the experimentally
measured binding affinity data for complexes deposited in the
Protein Data Bank (PDB). The 2017 release provides binding
data of a total of 17 900 biomolecular complexes, including pro-
tein–ligand (14 761), nucleic acid–ligand (121), protein–nucleic
acid (837), and protein–protein complexes (2181), the largest col-
lection of this kind. It connects the energetic and structural infor-
mation of these complexes, helpful for computational studies on
molecular recognition in biological systems.
Binding MOAD (Ahmed et al., 2015) (http://bindingmoad.
org/) is focused on well-resolved protein crystal structures with
a resolution better than 2.5 Å with clearly identified biologically
relevant ligands annotated with experimentally determined bind-
ing data. The latest database update in 2014 included 25 769 pro-
tein–ligand structural complexes from the PDB, 12 440
non-covalently bound ligands, and 9142 binding data.
The Affinity Database AffinDB (Block, 2006) (http://pc1664.
pharmazie.uni-marburg.de/affinity/) contains affinity data for
protein–ligand complexes of the PDB. Its purpose is to provide
direct and free access to the experimental affinity of a given com-
plex structure. As of January 11th, 2018, AffinDB contained 748
affinity values covering 474 different PDB complexes.
The SCORPIO database (Olsson et al., 2008) (http://scorpio2.
biophysics.ismb.lon.ac.uk/) is a free online repository of protein–
ligand interaction enthalpies measured by ITC. It holds 31 differ-
ent proteins, 173 ligands, approximately 400 ITC datasets, 118
crystal structures, and approximately 90 unique protein–ligand
complexes with both thermodynamic and structural data.
However, no significant correlations have been observed that
would enable a deeper understanding of the recognition phe-
nomenon despite the attempts to select only intrinsic binding
data.
All these databases (Inhester and Rarey, 2014) have been of
great importance but since most data were presented without a
significant selection of intrinsic data, it is difficult to observe sys-
tematic correlations that would help to understand the protein–
ligand recognition energetics. Figure 1 shows a general illustration
of the intrinsic thermodynamic parameters.
In an effort to investigate the correlations between compound
structure and the energetics of interaction with the target proteins,
we have chosen a system of human carbonic anhydrases (CAs)
and their well-known inhibitors, aromatic primary sulfonamides.
The system is convenient both from the chemical compound and
the protein side thus allowing a large set of data to be accumu-
lated. There are 12 catalytically active isoforms (isozymes) of
CAs in the human body. Every isoform contains ZnII in the active
site of the enzyme where the amino group of the sulfonamide
inhibitor binds via a coordination bond. This pharmacophoric
group orients the compounds to bind specifically to the active
site and the anchor-like interaction with the ZnII significantly
increases the affinity of the inhibitor to the CA. Synthetic varia-
tions of the aromatic sulfonamide are quite easy to prepare and
thus a large library of aromatic sulfonamide compounds was syn-
thesized by varying the substituents on the aromatic ring.
Furthermore, a large set of sulfonamide compounds has already
been clinically used as human drugs for several decades.
Intrinsic thermodynamic and kinetic parameters of these inhibi-
tors were determined by biochemical enzyme inhibition methods
and biophysical direct interaction assays described below. A large
collection of X-ray crystal structures have also been determined by
a number of laboratories.
Overview of CA isoforms in the human body
The enzyme that catalyzes liberation of the body’s CO2 from
HCO−3 from blood in the lung was discovered in 1932–33 by
Norman U. Meldrum and Francis J. W. Roughton in
Cambridge and William C. Stadie and Helen O’Brien at the
University of Pennsylvania (Meldrum and Roughton, 1932,
1933a, 1933b; Stadie and O’Brien, 1933a, 1933b; Chegwidden
et al., 2000; Forster, 2000).
There are several evolutionarily unrelated CA gene families
(Dodgson et al., 1991). However, only the enzymes of the alpha
family are expressed in humans, of which there are 15 isoforms
(isozymes). Twelve of these isoforms are catalytically active,
while three are inactive because they lack ZnII in the active site
due to mutations of His residues that bind the ZnII. As schemati-
cally shown in Fig. 2, human CA isoforms exhibit different cellu-
lar localization and multimerization patterns. There are a number
of books and reviews that describe CAs from human and other
organisms in great detail (Dodgson et al., 1991; Chegwidden
et al., 2000; Supuran et al., 2004; Frost and McKenna, 2014).
In this work, we limit the set of proteins to the 12 catalytically
active human CA isoforms because a potential drug would have to
demonstrate selectivity towards one target isoform and not exhibit
a toxic effect by inhibiting other vital non-target isoforms.
The first X-ray crystal structure of a carbonic anhydrase was
solved by Liljas et al. (1972). It showed that CA is primarily a
beta-sheet-structured protein. Later structures of other CA iso-
forms showed that the proteins have not only highly homologous
sequences, but also highly similar 3D structures (as shown in
Fig. 3 where five human CA isoforms have been superimposed).
The CAs catalyze the reversible CO2 hydration reaction:
CO2 +H2OOHCO−3 +H+ (1)
This reaction is spontaneous but the enzyme may accelerate the
achievement of equilibrium by up to approximately a million fold.
Fig. 1. General illustration of the term intrinsic. The standard observed Gibbs energy
of a protein–ligand binding depends on various non-essential experimental condi-
tions if there are binding-linked reactions that require energy consumption in
order for the binding reaction to occur. The standard intrinsic Gibbs energy of bind-
ing is obtained by summation of the energies from those linked reactions. The intrin-
sic energy is thus always greater than the observed and the intrinsic affinity is greater
than the observed. The same argument applies to all thermodynamic and kinetic
parameters as will be demonstrated below for the case of CA where the
binding-linked reactions are protonation reactions of the protein, the ligand, and
the compensation by the buffer.
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Human CA isoforms possess different specific enzymatic activities.
IsoformsCA II andCA IX are considered to be themost active (Hilvo
et al., 2008) while isoform CA III is the least active isoform. Catalytic
activities of recombinant CAs and the catalytic mechanism have pre-
viously been described (Krishnamurthy et al., 2008; Supuran, 2008).
The CAs are implicated in numerous diseases. For example,
CA IX is scarcely expressed in healthy human tissue (stomach/
duodenum, gallbladder, and body cavity linings), but highly over-
expressed in numerous solid hypoxic tumors (Pastorekova et al.,
2007). This makes CA IX an attractive anticancer target.
Indeed, inhibitors that possess high affinity and selectivity
towards CA IX over other CA isoforms are currently the focus
of anticancer drug development programs.
Overview of CA inhibitors
According to Davenport (1984), the history of CA inhibitors
begins with David Keilin who discovered that sulfonamides
inhibit CAs. Schwartz tried sulfanilamide as a diuretic in 1940
while Roblin and Clapp at the American Cyanamid Company
synthesized acetazolamide in 1949. Later, thiazides and
furosemide-type drugs were extensively used for the treatment
of hypertension and edema. These and other primary sulfon-
amides (R—SO2NH2) are now classical inhibitors of CAs, many
of them are still used in the clinic.
The sulfonamide amino group of the inhibitor makes a coor-
dination bond with the catalytic ZnII thus preventing CO2 or
HCO−3 from binding and competitively inhibiting the CO2 hydra-
tion reaction. The primary sulfonamides may be considered tran-
sition state analogs with respect to their mode of active site
binding (Fig. 4).
Some clinically used CA inhibitors are not only sulfonamide
derivatives, but also sulfamates (R—O—SO2NH2) (Supuran
et al., 2003; Smith and Jones, 2008; Carta et al., 2014). These
drugs are used to treat various diseases such as glaucoma
(Masini et al., 2013), potentially obesity (Scozzafava et al.,
2013), epilepsy (Aggarwal et al., 2013), or act as diuretics
(Supuran, 2008). Numerous new sulfonamide derivatives have
been reported in published patents and articles describing the
development of novel compounds (Carta et al., 2012a;
Lomelino and McKenna, 2016). Their binding affinity and selec-
tivity depend on the aromatic/heterocyclic scaffold of sulfonamide
and the functional groups linked to this scaffold. One of them is
in clinical trials for the treatment of hypoxic, metastatic tumors
(Lou et al., 2011; Supuran, 2017).
Several new classes of CA inhibitors have been developed, and
their inhibitory activity and the binding mechanism extensively
reviewed (De Simone et al., 2013; McKenna and Supuran, 2014;
Lomelino and McKenna, 2016; Supuran, 2017). Like sulfon-
amides, various compounds were found to bind directly to the
ZnII in the active site i.e. dithio-/monothiocarbamates (Carta
et al., 2012a), xanthanes (Carta et al., 2013; Abellán-Flos et al.,
2015), hydroxamates (Di Fiore et al., 2012), boronic acids and
borols (Chazalette et al., 2001; Winum et al., 2009). Among the
inhibitors that anchor to the metal ion coordinated water are phe-
nols (Innocenti et al., 2010; Maresca et al., 2015; Karioti et al.,
2016), polyamines (Carta et al., 2010; Davis et al., 2014), sulfocou-
marins (Tanc et al., 2013; Tars et al., 2013), thioxocoumarin
(Ferraroni et al., 2016), and carboxylic acids (Martin and
Cohen, 2012). It was found that carboxylic acids can also bind
outside of the active site (D’Ambrosio et al., 2015). Another
large group of CA inhibitors is coumarins which on hydrolysis
bind at the entrance to the active site (Maresca et al., 2009;
Touisni et al., 2011). The same binding mechanism is proposed
for fullerenes binding to CA (Innocenti et al., 2010a). Saccharin
and its derivatives were identified as CA inhibitors. However,
their binding mechanism has not been determined (Köhler
et al., 2007; D’Ascenzio et al., 2014) and there are inconsistencies
regarding their affinity measurements derived from different
Fig. 2. Localization and multimerization of catalytically active 12 human CA isoforms
in the cell. Isoforms CA I, CA II, CA III, CA VII, and CA XIII are cytosolic, CA VA and CA VB
are found in mitochondria, CA VI is excreted in human saliva and milk, CA IV is
anchored to the membrane via a covalently attached lipid moiety, and CA IX, CA
XII, and CA XIV are membrane-bound via a single transmembrane alpha helix with
the catalytic domain being outside of the cell. The remaining three isoforms
(named CARP – CA-related protein), CA VIII, CA X, and CA XI are catalytically inactive
and not shown in the figure. The CA VI, CA IX, and CA XII are dimers while the rest are
monomers. The CA IX bears a proteoglycan-like (PG) domain – a unique feature of
CA IX.
Fig. 3. Overlay of the backbones of five human CA isoforms shown in different colors
(CA I – blue, CA II – grey, CA VII – yellow, CA IX – red, and CA XII – green). Their back-
bones superimpose essentially identically.
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methods (Morkūnaitė et al., 2014). It was shown that secondary
and tertiary sulfonamides inhibit CA activity (Alp et al., 2013).
As seen from the above list, there are many chemical com-
pounds that are inhibitors of CA. The newest ones are mostly
not sulfonamides. They have been reviewed elsewhere and are
not subject of this paper. We limited this work to the primary sul-
fonamides that have a well-established 1 : 1 molecular binding
mechanism and are thus convenient for a detailed structure–ther-
modynamics analysis. Furthermore, as will be discussed below, it
is essential to correlate the intrinsic binding parameters with the
structures and not the observed parameters that are usually listed
in the literature on CA inhibitors. We included in this paper only
the compounds where the intrinsic binding data has been deter-
mined and thermodynamic/kinetic parameters confirmed by sev-
eral techniques.
Assays to determine small molecule inhibitor interaction
with CA
There are many assays of protein–ligand interactions that have
been applied to study CA inhibitors. These multiple methods
have been extensively reviewed by Krishnamurthy et al. (2008).
Here we describe and compare five biochemical and biophysical
techniques. The methods are not only convenient but also neces-
sary and sufficient for the characterization of CA–sulfonamide
interactions:
• SFA – the stopped-flow kinetic assay of inhibition of CA enzy-
matic activity, hydration of CO2 to HCO
−
3 and H
+,
• ITC – isothermal titration calorimetry, a technique that deter-
mines the affinity, enthalpy, entropy, and heat capacity of
interaction,
• FTSA – the fluorescent (fluorescence-based) thermal shift assay
(commonly termed ThermoFluor or differential scanning fluo-
rimetry (DSF)), an assay that determines the affinity of interac-
tion by following the thermal stabilization of the protein,
• SPR – surface plasmon resonance, an assay that determines the
kinetics of interaction including the rates of association and
dissociation,
• FPSA – fluorescent pressure shift assay (also known as
PressureFluor), a rarely used assay that determines the volume
change of the system upon interaction.
We have concluded that at least two assays should be used to
confirm novel inhibitors and all of these assays have drawbacks
and limitations and contribute a different kind of information
as will be discussed below.
Stopped-flow assay of the inhibition of CA enzymatic activity
(SFA)
Inhibitors of proteins that possess enzymatic activity and thus are
enzymes are often discovered by performing biochemical assays
that determine the inhibition of enzymatic activity. Such assays
must be developed individually for each enzyme and are often
quite tedious and material and time-consuming. The CA activity
is often determined by the stopped-flow spectrophotometric
method by following the decrease in absorbance of a pH indicator
(e.g., phenol red) because of the drop in pH due to the protons
appearing from the CO2 hydration reaction catalyzed by the
CA, Eq. (1). The assay is well-described elsewhere (Khalifah
et al., 1977; Smirnovienė et al., 2017) and its limitations will be
discussed below.
Isothermal titration calorimetry (ITC)
ITC is one of the most commonly used techniques to determine
protein–ligand interactions (Chaires, 2008; Krimmer and Klebe,
2015; Callies and Daranas, 2016; Falconer, 2016; Renaud et al.,
2016; Vega et al., 2016). However, the technique requires a rela-
tively large amount of pure protein and compound. The tech-
nique is isothermal and thus can be fully performed at a
physiological temperature, e.g., resembling the conditions in the
human body. The reaction is performed by titrating the protein
with the compound in the calorimeter cell that measures the
heat evolved by the interaction of known quantities of binding
partners. The heat is a universal observable in any reaction.
Method development is dictated solely by the components of
titration and hence straightforward. However, it is not always
straightforward to interpret the data obtained. The heat of reac-
tion determined by the calorimeter is equal to the thermodynamic
parameter enthalpy, under two conditions that there is no work
performed and the pressure is constant. Thus ITC provides a
direct route to a determination of the enthalpy of interaction.
The experiment is performed in such a way that the ligand is
injected in aliquots and thus the evolved heats are proportional
to the fraction of ligand bound to the protein. From the direct
determination of ligand-bound fraction, one can calculate the
equilibrium binding/dissociation constant (and hence affinity)
for the interaction. Knowledge of the equilibrium constant per-
mits the calculation of the change in Gibbs energy of binding:
DG = −RT ln(Kb) (2)
The standard entropy change upon interaction can also be
determined from the same experiment by subtracting the Gibbs
Fig. 4. Comparison between interactions of primary aro-
matic sulfonamide, and bicarbonate with the CA.
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energy from enthalpy:
DS = (DH − DG)/T (3)
The binding of 1 (EZA, all compound structures are shown in
Supplementary Table 1) to the catalytic domains of catalytically
active human recombinant CAs as determined by ITC is shown
in Fig. 5. It is clear that, for example, 1 bound CA I significantly
weaker than CA II under the assay conditions. Furthermore, the
observed enthalpy of interaction was significantly more exother-
mic (more negative) for CA II than for CA I. For every reaction,
the molar ratio necessary to reach the midpoint of titration was
approximately 1.0. Thus, essentially all 100% of the protein was
able to bind the ligand to achieve saturation. This indicates that
both the protein and compound preparations were highly pure.
Fluorescent thermal shift assay
FTSA, also commonly termed DSF, or ThermoFluor (when per-
formed in a high-throughput plate format) is the assay that deter-
mines the melting (unfolding or denaturation) temperature Tm of
the protein in the absence and the presence of increasing concen-
trations of a ligand. The Tm may be determined by fluorescence or
by differential scanning calorimetry (DSC) (Brandts and Lin,
1990). The assay may follow the intrinsic protein fluorescence
of tryptophan or tyrosine residues as the protein unfolds and
Fig. 5. Examples of ITC data of 1 binding to catalytically active recombinant human CA isoforms at pH 8, 25 °C as determined using the VP-ITC calorimeter. Insets
show the raw curves with unflattened baselines, without user-biased interference. Experiments were performed in 50 mM sodium phosphate buffer containing
100 mM NaCl and 2% DMSO as previously described in: CA I and CA II (Morkūnaitė et al., 2015), CA IV (Mickevičiūtė et al., 2017), CA VB (Kasiliauskaitė et al.,
2016), CA VI (Kazokaitė et al., 2015), CA VII (Pilipuitytė and Matulis, 2015), CA IX (Linkuvienė et al., 2016b), CA XII (Jogaitė et al., 2013), and CA XIII
(Baranauskienė and Matulis, 2012). All panels are drawn at the same scale to help visualize the differences both in enthalpies and affinities of binding. No
data have been determined at comparable conditions for CA III, CA VA, and CA XIV.
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the environment of these residues changes. Alternatively, the
fluorescence of a solvatochromic probe such as ANS (1,8-anilino-
naphthalene sulfonate) (Anderson and Weber, 1969; Slavik, 1982;
Matulis and Lovrien, 1998; Matulis et al., 1999; Cimmperman and
Matulis, 2011) or Sypro Orange (Lo et al., 2004; Niesen et al.,
2007) can be followed as the probe binds to the exposed hydro-
phobic residues upon protein unfolding. FTSA is a less-widely
used technique than ITC, but its use has significantly increased
when compound libraries are screened to determine the best
binders to target proteins (Pantoliano et al., 2001; Yanchunas
et al., 2005; McDonnell et al., 2009). The assay is relatively easy
and robust and does not require assay development for a partic-
ular protein–ligand system. However, data interpretation some-
times may not be fully straightforward (Cimmperman et al.,
2008; Cimmperman and Matulis, 2011).
In the assay, a series of wells with the constant protein concen-
tration are prepared and various compound concentrations are
added. The mixture is heated and the melting curves at all com-
pound concentrations are recorded simultaneously in approximately
1 hour. The melting curves are fit to the 2-state (native-unfolded)
model (Matulis et al., 2005; Cimmperman et al., 2008) providing
the Tms at various compound concentrations. These Tm dependen-
cies on compound concentration are fit to the model that includes
the thermodynamic parameters of protein unfolding and ligand
binding (Cimmperman et al., 2008) yielding the affinity of the inter-
action (the dissociation constant Kd).
The binding affinities of 1 to all 12 catalytically active human
CA isoforms determined by FTSA are shown in Fig. 6. The plots
show the 1 dosing curves (where the compound concentration is
on a logarithmic scale), while the insets show the melting curves
Fig. 6. Example of FTSA data of 1 binding to all 12 catalytically active recombinant human CA isoforms at pH 6. The insets show raw melting curves obtained by
following ANS fluorescence. The experiments were performed at pH 6 in universal buffer made of 50 mM sodium phosphate, 50 mM sodium acetate, and 25 mM
sodium borate containing 100 mM NaCl and up to 2% DMSO and 50 µM ANS as previously described: CA I and CA II (Morkūnaitė et al., 2015), CA IV (Mickevičiūtė
et al., 2017), CA VB (Kasiliauskaitė et al., 2016), CA VI (Kazokaitė et al., 2015), CA VII (Pilipuitytė and Matulis, 2015), CA IX (Linkuvienė et al., 2016b), CA XII (Jogaitė
et al., 2013), CA XIII (Baranauskienė and Matulis, 2012), and CA XIV (Juozapaitienė et al., 2016).
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with various added inhibitor concentrations. Compound 1 stabi-
lized each CA isoform to a different extent. For example, CA III
was stabilized by only several degrees, thus showing that this iso-
form binds the ligand weakly. However, CA IX was stabilized by
more than 10° indicating strong interaction. In addition, the assay
yielded stabilities of all CA isoforms in the absence of ligand at
these assay conditions. It should be kept in mind that direct com-
parison between the ΔTms is usually valid only when the proteins
are of similar molecular mass.
Surface plasmon resonance
SPR is also a commonly used technique to determine protein–
ligand interactions and has been extensively reviewed (Myszka
and Rich, 2000; Patching, 2014; Olaru et al., 2015; Renaud
et al., 2016). The technique determines the protein–ligand associ-
ation and dissociation rates. Therefore, it is often used to deter-
mine the kinetics of interactions. The inverse of the dissociation
rate is equal to the residence time, a commonly used characteristic
of the drug lead–protein pair. We will go in more detail on the
assay in the section on sulfonamide–CA interaction kinetics.
Advantages and limitations of SFA, FTSA, and ITC
Here we emphasize that for the most complete picture of a studied
binding reaction a multi-technique-based approach is recom-
mended. We use all of the above-described assays for many CA
inhibitors. Each technique has numerous advantages and disad-
vantages (Renaud et al., 2016). However, due to limitations in
time and material, and the necessity to test as many chemical
compounds as possible, some techniques may be more suited
than others.
In Fig. 7, we compare the advantages and limitations of SFA,
FTSA, and ITC. Panels on the left show simulated data while
examples of observed data are shown on the right. The main lim-
itation of SFA is that the IC50 may only be determined down to
Fig. 7. Comparison of SFA, FTSA, and ITC techniques, their advantages and limitations. Panels on the left show simulated curves, while on the right – the examples
of measured data. The figure is adapted from Smirnovienė et al. (2017). (a) The application of Hill equation at protein concentration Pt = 10nM and various values of
apparent IC50. The assay would not distinguish between 1 nM and 1 pM compounds because Pt cannot be reduced to less than 1 nM or 1 pM to obtain distinguish-
able dosing curves of nanomolar (solid line) or picomolar (dotted line) affinity. (b) Experimental data of an interaction between CA II-307 at several compound
concentrations. Data points were fitted according to the Hill equation with varied Hill coefficient. The inset shows the raw absorbance curves at several compound
concentrations. (c) The simulated FTSA dosing curves for different binding affinities (Kd from 1 pM to 1 mM) are shown. These curves were generated using the
following set of parameters: T = 37 °C, Pt = 10 µM, enthalpy of CA II unfolding is 690 kJ mol
−1, heat capacity of unfolding is 17 kJ mol−1 K−1, enthalpy of binding
is −42 kJ mol−1, heat capacity of binding is −0.8 kJ mol−1 K−1 , and the melting temperature Tm without added ligand is 60 °C. (d) Experimental FTSA data of CA
I-323 (squares), CA II-10 (circles), and CA XIII-310 (triangles). The insets show raw melting curves at 0 and 200 µM inhibitor concentrations. (e) Simulated ITC curves
using a single binding site model of different binding affinities at Pt = 10 µM. ( f) Experimental ITC curves of the same binding interactions as in panel D. Affinity of
CA I-323 is too strong to be determined by ITC but FTSA assay provides accurate Kd.
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about Pt/2 (half of the protein concentration) (Copeland, 2005).
Despite being one of the fastest known enzymes, the concentra-
tion of any CA isoform cannot be reduced below 10 nM even
for the most active CA II and CA IX and, therefore, the IC50 can-
not be determined below approximately 5 nM. The dotted and
solid curves in Fig. 7a show the position of the dosing curves if
the protein concentration was 10 nM. The lines almost completely
coincide with each other and, therefore, the compounds with
picomolar affinities cannot be distinguished from nanomolar
ones. In order to distinguish the curves, one would need to signif-
icantly reduce the protein concentration. This cannot be done in
most cases and thus the Ki of CA inhibitors cannot be determined
below approximately 2 nM.
Furthermore, some isoforms possess significantly lower spe-
cific enzymatic activity and thus their concentration in the assay
must be increased. For example CA I is approximately 10-times
less active than CA II. Therefore, the lowest Ki that can be deter-
mined for inhibitors of CA I at the same conditions is approxi-
mately 20 nM. This may lead to incorrect assignment of
inhibitor selectivity towards CA II over CA I based on SFA alone.
Another significant disadvantage of SFA is that, as shown in
Fig. 7b, if the protein concentration is varied, the dosing curves
also shift and thus the Ki could appear to vary dependent on
the concentration used in the assay. If the experiment is per-
formed at a single CA concentration, the obtained values may
be inaccurate. Therefore, SFA should be used with care keeping
in mind the applied protein concentration in the assay that limits
the Ki reachable in the assay.
In FTSA (Fig. 7c), there are essentially no limitations in affinity
determination, thus picomolar and millimolar compounds may
be easily distinguished in the same assay. At the simulated condi-
tions, the picomolar compound would shift the temperature by
over 20 °C, while the millimolar compound – by only 1° or 2°
dependent on the added concentration. In order to detect milli-
molar compounds, it would be necessary to add a 10 mM com-
pound. Figure 7d shows examples of the observed data. The
limitation of FTSA is that the assay cannot be used for highly sta-
ble proteins that melt at temperatures over 90 °C. However, CAs
denature around 55–65 °C. Thus, FTSA has a significant advan-
tage over SFA because strongly-interacting picomolar compound
Kds may be determined correctly by FTSA and not by SFA.
The main disadvantage of FTSA compared with SFA is that it
does not determine whether the compound is actually an inhibi-
tor of the enzyme or just a binder. Ligands potentially may bind
to various sites on CA surface, stabilize the protein, and be erro-
neously assigned to be an inhibitor of CA. Therefore, the SFA is a
necessary confirmatory technique to demonstrate that the com-
pound is actually an inhibitor of enzymatic activity. However,
the affinity of an inhibitor will still be determined more accurately
by FTSA than SFA. Since primary sulfonamides bind to the active
site in a well-established way, both techniques yield the same Kd
or Ki when the assays are properly performed.
The simulated curves of the third assay, ITC, are shown in
Fig. 7e. The assay has optimal accuracy when the curve is of sig-
moidal shape, such as the dashed curves (Kd = 100 − 1000 nM). If
the compound binds weakly, for example in the micromolar
range, the curve becomes too flat and may be indistinguishable
from the curve of compound dilution, thus potentially leading
to erroneous assignment of the observed data to a binding reac-
tion. In such a situation the protein concentration must be raised,
if the solubility of both components permits, expanding the win-
dow of affinity determination. On the other hand, if the
compound has a Kd of 1 nM or tighter, the curve is too steep
and the Kd again cannot be determined. It may be stated that
‘the binding is 10 nM or tighter’, but the actual affinity cannot
be determined. In such a situation, the protein solution may be
diluted as long as the signal remains sufficiently above the noise
level.
The main advantage of ITC is that it is the only assay that may
be used to directly determine the enthalpy of protein–ligand bind-
ing. It is also the most accurate technique to obtain the entropy
and heat capacity of interaction. The change in enthalpy is
most accurately determined when the binding is tight, i.e. nano-
molar or tighter. It is nearly impossible to determine the change
in enthalpy of weakly binding compounds by direct ITC titration
(displacement titration may be sometimes used instead). Raising
the protein concentration increases the range, but may not be
practical in some cases.
Due to the above-described limitations, it is good to combine
FTSA-determined Kd and the enthalpy determined by ITC. It is
not possible to accurately determine subnanomolar Kd values
from ITC without applying displacement ITC techniques that
are not discussed here in detail, but have been introduced and
reviewed previously (Krainer et al., 2012; Krainer and Keller,
2015).
Comparison of the observed Kd,obs values obtained by the
above-described four techniques is shown in Fig. 8. The FTSA
is the most robust technique in our opinion, there is essentially
no substrate (CO2) present (concentration of CO2 from the air
is significantly below the KM of any CA), and the assay is practi-
cally without limits of the range (accessing Kd,obss from at least
pM to mM or greater). Therefore all compound interaction
with CA isoforms has been determined by FTSA. Only a fraction
of the compound affinities has been determined by the other
three techniques.
ITC cannot accurately determine the Kd below 1 nM if we keep
the protein concentration around 10 μM because the Wiseman c
factor, equal to the product of the Kb and protein molar concen-
tration for 1 : 1 binding reactions, which shows the steepness of
the titration curve (see Fig. 7 and should be in the range of
approximately 5–500), (Wiseman et al., 1989) reaches 1000.
Some increase of the accessible range may be achieved by reduc-
ing the protein concentration. Here we see (Fig. 8a) that there is a
decent correlation between the affinities determined by FTSA and
ITC in the 100 nM Kd range, but the ITC-determined values tend
to show reduced affinities relative to FTSA in the 1–10 nM range.
ITC thus tends to underestimate the single-digit nanomolar affin-
ities. It is also important that the spread of data may reach up to
10-fold in affinity when comparing ITC with FTSA.
There was a quite good correlation between the affinities deter-
mined by FTSA and SFA (Fig. 8b). As discussed above, it is
important to use SFA to confirm that the compounds are inhib-
itors of the enzymatic activity. In the case of CA inhibitors,
because all compounds, reviewed in this paper, are primary sul-
fonamides with a well-described mode of binding by a number
of techniques, we do not perform the SFA for all compounds
due to several reasons. First, the assay cannot determine the
IC50s below the protein concentration, which is approximately
10 nM (Smirnovienė et al., 2017). Second, the assay is signifi-
cantly more costly both in time and materials to justify its perfor-
mance for all studied compounds.
The bottom panel (Fig. 8c) compares the affinities obtained by
FTSA and SPR. The SPR technique is commonly used to deter-
mine both the affinity and the kinetics of compound association
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and dissociation from CA (Redhead et al., 2015; Talibov et al.,
2016). Similarly to the other three techniques, the spread or
uncertainty of the data is quite similar.
Table 1 lists and provides some examples of Kd,obs and Ki val-
ues obtained by SFA, FTSA, ITC, and SPR (Smirnovienė et al.,
2017). In cases, where the four techniques yielded different values,
the bold numbers show the correct determination of the affinities.
For some ligands of average affinity, all four techniques yielded
the same value. For example, the binding and inhibition constants
of 187 interactions with CA I, CA II, CA VII, CA XII, and CA
XIII were essentially the same by all techniques. However, for
example, the binding affinities of 323 to CA I, and of compounds
369 and 341 to CA IX could be correctly determined only by
FTSA. The remaining three assays, SFA, ITC, and SPR, confirmed
that the interaction is very strong, but could not reach the actual
affinity value due to above-described limitations.
Volume change upon protein–ligand binding
The above-described assays provide means to determine inhibi-
tion and inhibitor binding thermodynamic and kinetic param-
eters. However, the picture of protein–ligand interaction can be
significantly enhanced by the determination of volumetric
properties of the interactions. Unfortunately, the majority of
studies are limited to the techniques, which exploit only the
temperature as a thermodynamic variable and avoid studying
pressure effects because such techniques are much more
laborious.
There are several techniques that are capable of determining
the volume of protein–ligand binding: the fluorescent pressure
shift assay (PressureFluor, FPSA) (Toleikis et al., 2011, 2016;
Skvarnavičius et al., 2017), vibrating tube densitometry(Barbosa
et al., 2003; Son et al., 2012; Toleikis et al., 2016), and the high-
pressure NMR (Wilton et al., 2009; Roche et al., 2012; Toleikis
et al., 2016). They can determine the change of system volume
and compressibility caused by the bound ligand. The volumetric
assays have been described previously by Carey et al. (1977);
Barbosa et al. (2003); Chalikian and Filfil (2003); Wilton et al.
(2009); Toleikis et al. (2011, 2012, 2016); Roche et al. (2012);
Petrauskas et al. (2013); Voloshin et al. (2015); Skvarnavičius
et al. (2017). However, there is relatively little data available in
the literature on any protein–ligand system, not mentioning
the CA, and it is difficult to judge yet if these approaches will
be useful in the design of ligands with desired binding
properties.
Observed versus intrinsic thermodynamic binding
parameters
Intrinsic affinity of binding
Sulfonamides are by far the largest class of compounds that are
inhibitors of CAs. However, despite the long history and impor-
tance of sulfonamides as CA inhibitors, there still remains uncer-
tainty in their binding mechanism. As first identified by Taylor
et al. (1970), the binding kinetics of sulfonamide inhibitor to
CA II is dependent on pH and the dependence has a U-shape,
interaction is fastest near neutral pH and slows down towards
acidic and alkaline regions. Application of FTSA, ITC, and SPR
techniques also showed that the binding affinity is strongest
near neutral pH and decreases both in the acidic and alkaline
regions. The affinity decreases exactly tenfold with one pH unit
both in the acidic and alkaline regions. This indicates that the
CA-sulfonamide binding reaction is coupled to at least two pro-
tonation–deprotonation reactions. As pointed by Taylor et al.
(1970), there are four possible ways for the sulfonamide com-
pound to bind the CA, shown in Eqs. (4)–(7).
CA− ZnII−OH− + RSO2NH2
O CA− ZnII − NH2SO2R +OH−
(4)
Fig. 8. Comparison of the experimentally determined Kd,obs obtained by four tech-
niques: fluorescent thermal shift assay (FTSA), isothermal titration calorimetry
(ITC), stopped-flow assay of the inhibition of CA enzymatic activity, CO2 hydration
(SFA), and the surface plasmon resonance (SPR). All Kds have been determined by
FTSA as the most robust and reliable technique and compared with the results
obtained for a portion of compounds by ITC, SFA, and SPR. The FTSA practically
does not have limits or range of reliable determinations, the compound Kds may
be determined from pM to mM affinity range in a single experiment, while the
other three techniques have limitations of the range where reliable determinations
may be made, shown with arrows and shaded in grey.
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Table 1. Comparison of binding and inhibition constants of CA I, CA II, CA VI, CA VII, CA IX, CA XII, and CA XIII obtained by SFA (pH 7.0–7.5, 25 °C), FTSA, ITC (pH 7.0,
37 °C), and SPR (pH 7.0–7.4, 25 °C). SFA. The used KM values were, for CA I – 1.4 mM, CA II – 4.7 mM, CA VI – 6.9 mM, CA VII – 11.4 mM, CA IX – 6.9 mM, CA XII – 12 mM,
and CA XIII – 13.8 mM, taken from Supuran (2008). The IC50 is the 50% inhibition concentration of enzymatic activity obtained by Hill fit of the data. Ki is the
inhibition constant obtained after application of the Cheng–Prusoff equation to the IC50. The Kd,obs is the dissociation constant obtained via Morrison equation.
FTSA. The Kd,obs is the observed dissociation constant obtained by FTSA at the CA concentration 5 to 10 µM. ITC. The Kd,obs is the observed dissociation
constant obtained by ITC at the CA concentration of 4 to 10 µM. SPR. The Kd,obs is the observed dissociation constant obtained by SPR at the CA concentration
for immobilization of 75 µg ml−1 for CA I, 100 µg ml−1 for CA II, 25 µg ml−1 for CA VII, 100 µg ml−1 for CA IX, 25 µg ml−1 for CA XII, 75μg ml−1 for CA XIII as
described by Talibov et al. (2016). Values are shown in the regular font when the results match among three methods within an approximate error of ±2 fold.
Values are shown in bold to point the most reliable value when results are significantly different among the methods. Values are in italic to emphasize
unreliable results when the methods should not be used due to their limitations (for SFA – concentration of the enzyme above the concentration of inhibitor,
for ITC – Wiseman c-factor outside the required range). SFA, FTSA, and ITC data are taken from the references indicated next to the compound number. The
standard error of Kd measurements is ±2 times (Petrauskas et al., 2016; Linkuvienė et al., 2016a)
SFA
FTSA ITC SPR
Cpd. CA
[CA]
(nM)
[CO2]
(mM)
h
coef.
IC50
(nM)
Ki
(nM)
Kd,obs
(nM) Kd,obs (nM)
Kd,obs
(nM)
Kd,obs
(nM)
2 (Dudutienė
et al., 2014) AZM
CA I 300 11 1 400 45 290 2400 810 ND
CA II 13 14 1.3 14 4.6 10 46 46 15
CA II 50 13 1.1 ⩽35 ⩽9.2 10 46 46 15
CA II 100 16 2 ⩽50 ⩽12 10 46 46 15
CA
IX
20 12 1.3 18 6.4 6.7 21 22 8.5
CA
XII
40 9.9 1.4 45 25 25 130 130 ND
CA
XIII
100 7.9 2 ⩽60 ⩽38 ⩽10 120 60 37
187 (Kišonaitė
et al., 2014)
CA I 500 8.6 1 5600 780 5600 4300 2300 3500
CA II 20 8.9 1 220 76 220 330 430 130
CA
VII
50 7.3 1 830 470 830 710 660 370
CA
XII
100 8.6 1 1100 640 1100 1400 370 180
CA
XIII
500 11 1 450 250 250 330 270 180
323 (Dudutienė
et al., 2013)
CA I 33 16 1.1 ⩽12 ⩽0.9 ⩽2 0.4 ⩽12 ND
CA I 100 11 1.5 ⩽50 ⩽5.5 ⩽10 0.4 ⩽12 ND
CA I 300 11 2 ⩽150 ⩽17 ⩽20 0.4 ⩽12 ND
341 (Dudutienė
et al., 2014)
CA I 500 13 1 46 000 4500 46 000 24 000 ⩾10 000 ND
CA II 40 13 1 910 240 910 1000 730 ND
CA
IX
20 10 2 ⩽13 ⩽5.2 ⩽5.0 0.77 15 27
CA
XII
40 12 1 170 86 170 240 230 400
CA
XIII
150 14 1.3 180 90 130 98 420 ND
369 (Dudutienė
et al., 2014)
CA I 300 14 1 700 65 560 830 1100 ND
CA II 20 14 1 29 7.4 29 56 59 100
CA
IX
10 14 3 ⩽5 ⩽1.7 ⩽10 0.032 ⩽10 ND
CA
IX
20 17 3 ⩽10 ⩽2.9 ⩽10 0.032 10 ND
CA
XII
40 10 2 ⩽20 ⩽11 ⩽10 2.9 20 ND
CA
XIII
54 9.7 2 ⩽25 ⩽15 ⩽10 4.0 42 15
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CA− ZnII−OH− + RSO2NH−
O CA− ZnII −NH− SO2R + OH−
(5)
CA− ZnII −H2O+ RSO2NH2
O CA− ZnII −NH2SO2R +H2O
(6)
CA− ZnII−H2O + RSO2NH−
O CA− ZnII−NH− SO2R +H2O
(7)
The first possibility is that the electrostatically neutral (proton-
ated) sulfonamide replaces the OH− bound to the ZnII in the
active site of CA (Eq. (4)). Second, that the negatively charged sul-
fonamide replaces the OH− (Eq. (5)), third, that neutral sulfona-
mide displaces neutral water molecule (Eq. (6)), and the fourth,
that the deprotonated sulfonamide (negatively charged
SO2NH
−) replaces the H2O molecule coordinated by the Zn
II in
the active site of CA (Eq. (7)). The second and third reactions
have been already shown by the authors to be inconsistent with
the U-shape dependence on pH. However, both the first and
the fourth reactions seemed plausible and were difficult to
distinguish.
We are now convinced that the fourth reaction (Eq. (7)) is the
only or at least a dominant reaction that takes place when sulfon-
amides bind to a CA, meaning that the intrinsic binding reaction
is between the negatively charged sulfonamide to such form of CA
where the fourth ligand bound to the ZnII in the active site is elec-
trostatically neutral water molecule. The first indication that the
fourth reaction occurs was the spectral evidence on Co-containing
CA enzyme (Engberg and Lindskog, 1984; Tu and Silverman,
1986). However, a more recent neutron-diffraction crystal struc-
ture of acetazolamide bound to CA II from McKenna laboratory
(Fisher et al., 2012b) directly showed that the sulfonamide amino
group possesses only one proton and thus the group is deproto-
nated and negatively charged when bound to the CA II. Our
data are consistent with this conclusion. However, it is difficult
to distinguish the fourth possibility from the first using thermo-
dynamic methods alone.
At neutral pH 7, most sulfonamides are almost fully proton-
ated since their pKas are usually around 9 or 10, in the form
that is unable to bind. However, a small fraction is deprotonated
and binds to CA. When the deprotonated form is depleted, addi-
tional sulfonamide deprotonates to keep the fraction unchanged.
This additional sulfonamide also binds to CA and so on until
the enzyme is fully saturated with the inhibitor.
Similarly, only a part of the ZnII-coordinated molecules are in
H2O form because the pKas of most human CAs is approximately
7. Thus, approximately half of CA fraction is deprotonated and
must undergo protonation in order to bind the sulfonamide
anion. When these linked reactions (Eq. (8)) occur, the proton
must be uptaken from the buffer or released to the buffer (Fig. 9).
Intrinsic : CA− ZnII−H2O+ RSO2NH−
O CA− ZnII−NH− SO2R +H2O
Ligand : RSO2NH
− + H+ O RSO2NH2
Protein : CA− ZnII−OH− +H+O CA− ZnII−H2O (8)
Buffer : Buf +H+O BufH+
Observed : Intrinsic + Ligand + Protein + Buffer
The fraction of deprotonated sulfonamide is dependent on the
sulfonamide amino group pKa,SA and can be calculated using
Eq. (9):
fRSO2NH− =
10pH−pKa,SA
1+ 10pH−pKa,SA (9)
Fig. 9. The model of the linked reactions (also shown as Eq. (8)), occurring upon sulfonamide ligand binding to CA. A sum of several binding-linked reactions occur
that we observe by any experimental technique, but the Quantitative Structure–Activity Relationship (QSAR)-type analysis requires that we analyze only the intrinsic
reaction and correlate the intrinsic affinity and other intrinsic parameters with the structure of the ligand and the ligand–protein complex. The linked contributing
reactions must be subtracted from the observed ones to obtain the intrinsic reaction.
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Similarly, the fraction of binding-ready CA depends on pH
and the pKa,CA of the water molecule in the active site and can
be calculated using Eq. (10):
fCAZnH2O =
10 pKa,CA−pH
1+ 10 pKa,CA−pH (10)
The affinity of interaction will be reduced by the amount how
much the fractions are reduced. In other words, the observed
binding constant Kb,obs indicates us a diminished Kb,int due to
reduced fractions. The intrinsic Kb,int can be calculated using
Eq. (11):
Kb,int = Kb,obsfCAZnH2O × fRSO2NH−
(11)
Figure 10 shows the relationship between the intrinsic and
observed affinities and the dependence of the latter on pH. The
intrinsic affinity is independent of pH, but because there are a
reduced fraction of both interacting components at both acidic
and alkaline pHs, there is energy needed to overcome this linked
reaction and therefore the observed affinity is reduced
In turn, the intrinsic Gibbs energy of binding can be calculated
using Eq. (12):
DGint = −RT ln(Kb,int) (12)
The change in the standard Gibbs energy of ligand binding
dependence on pH has a U-shape, similar to the Kd, but upside
down as Kb. Figure 11 shows that the U-shapes are obtained for
all catalytically active human CAs. All experimental techniques
discussed in this paper (FTSA, SFA, ITC, and SPR), yield the
U-shape inhibitor binding Gibbs energy dependence on pH. In
all cases, the affinity is strongest in near-neutral pH range and
decreases in both directions. The observed affinity comes closest
to the intrinsic value at near-neutral pH, but usually does not
reach it and thus is almost never observed experimentally.
Intrinsic enthalpy of binding
The change in the observed enthalpy on the binding, similarly to
ΔG, also has contributions from all linked processes, including
inhibitor deprotonation, protonation of the CA-bound hydroxide,
and the compensating buffer effects. Therefore, to get the change
in the intrinsic enthalpy on binding it is necessary to subtract all
linked processes as shown in Eq. (13):
DHint = DHobs − nSADHpr,SA − nCADHpr,CA
+ nbufDHpr,buf (13)
where ΔHobs – the observed enthalpy of binding obtained by
direct ITC titration, ΔHpr,SA – the enthalpy of protonation of
deprotonated inhibitor, ΔHpr,CA – the enthalpy of protonation
of the CA-bound OH−, and ΔHpr,buf – the enthalpy of buffer pro-
tonation. The ns denote the numbers of protons uptaken or
released:
nSA = fRSO2NH− − 1 (14)
is the number of protons released from the inhibitor to buffer
(ninh =−1 to 0),
nCA = 1− fCAZnH2O (15)
is the number of protons uptaken by the CA-bound OH− (nCA = 0
to 1),
nbuf = nSA + nCA (16)
is the net sum of protons uptaken by the buffer both from the
ligand and protein or released by the buffer to the ligand or pro-
tein (nbuf =−1 to 1).
The enthalpy of protonation of TRIS base is −47.45 kJ mol−1
and of HPO2−4 is −5.1 kJ mol
−1 at 25 °C (Goldberg et al., 2002).
If we perform sulfonamide–CA ITC titrations in various buff-
ers at various pHs as shown in Fig. 12, an X-shape dependence is
observed as shown in Fig. 13. At low pH, the observed enthalpies
(ΔHobs) in phosphate buffer are low in magnitude, while in TRIS –
significantly more exothermic. The difference between the
observed enthalpies is equal to the difference between the enthal-
pies of protonation of the two buffers. In alkaline region, the sit-
uation is reversed – the enthalpies in phosphate became much
more exothermic, while in TRIS – less exothermic. The red
solid line shows the position of the intrinsic enthalpy (ΔHint) of
1 binding to CA I. The intrinsic enthalpy is independent of pH.
The dashed line shows a hypothetical situation for the observed
enthalpy dependence on pH if the buffer had exactly zero
enthalpy of protonation (ΔHpr,buf = 0). The difference between
the dashed line and the intrinsic enthalpy in the acidic region is
equal to the enthalpy of inhibitor protonation (ΔHpr,SA), while
in the alkaline region – to the enthalpy of protonation of the
CA-bound OH− (ΔHpr,CA).
The same procedure has been performed with every purified
CA isoform and the data is shown in Fig. 14. All of the nine iso-
forms where the data has been obtained exhibited similar
X-shaped curves, but since the protein pKas were slightly different
and the intrinsic enthalpies of binding were also different among
isoforms, they yielded slightly different curves. It should be noted
that the precision of the enthalpies is really high, but there still
Fig. 10. Relationship between the intrinsic (independent of pH, shown as horizontal
line) and observed affinities (filled circles fit by the solid line of overturned U-shape)
of 1 binding to CA IX. The observed affinity is reduced both at acidic and alkaline pHs
due to reduced fractions of available binding-ready species (negatively charged sul-
fonamide, shown as solid red line, and CA, bearing the neutral water molecule,
shown as a dashed red line).
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were some discrepancies between the observed data and the
model curves, especially at the acidic and alkaline pH. We assume
that these discrepancies are due to protein destabilization.
However, an attempt was made to determine many more data
points for one isoform in one buffer. The data for CA XIII in
phosphate buffer are shown in Fig. 15.
Most researchers have based the choosing of the lead com-
pound for development on the observed parameters, observed
affinity or observed enthalpy. From the first glance, it may seem
that it is sufficient to experimentally determine the physiologically
relevant compound affinities. Thus, one may be interested in the
affinities observed at the pH 7.4. It seems that it is most relevant
to correlate the compound chemical structures with the binding
data obtained at such pH. However, this is only partially true
and may lead to erroneous conclusions. For example, if the bind-
ing affinities of two compounds are compared where the com-
pounds have highly different pKas (e.g., 8 and 11), then if the
compound with the pKa 8 is 1000-fold stronger binder than the
compound with pKa 11, one may assume that the first compound
is better attached to the CA. This conclusion is incorrect because
the higher affinity is entirely explained by the difference in the
pKa and both compounds would recognize the protein surface
with identical affinity.
As shown in this section, the observed enthalpies are not really
informative, instead, it is the intrinsic enthalpy change that
describes the interaction. The buffer, ligand, and protein
Fig. 11. The dependence of ΔGobs on pH determined by FTSA (filled circles) and ITC (open circles) methods at 25 °C. Circles show the binding of 1 and squares of
303 (to CA III and CA VA). Solid curve is a fit of the model, solid line is intrinsic Gibbs energy of binding, dashed line is a fraction of ligand, dotted line is a fraction of
protein. Experiments were performed in universal buffer made of 50 mM sodium phosphate, 50 mM sodium acetate, and 25 mM sodium borate containing 100 mM
NaCl and up to 2% DMSO as previously described in: CA I and CA II (Morkūnaitė et al., 2015), CA IV (Mickevičiūtė et al., 2017), CA VB (Kasiliauskaitė et al., 2016), CA VI
(Kazokaitė et al., 2015), CA VII (Pilipuitytė and Matulis, 2015), CA IX (Linkuvienė et al., 2016b), CA XII (Jogaitė et al., 2013), CA XIII (Baranauskienė and Matulis, 2012),
and CA XIV (Juozapaitienė et al., 2016). All panels are drawn at the same scale to help visualize the differences in affinities of binding.
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contributions may be so large that they may overwhelm the
enthalpy data and the compounds would thus be ranked in a
completely wrong order. Therefore, it is essential to determine
the mechanism and calculate intrinsic enthalpies to be able to
rank compounds in the order of increasingly exothermic enthalpy.
In this work, we attempted to determine intrinsic thermody-
namic parameters of a series of sulfonamide compounds to the
12 catalytically active human CA isoforms. Intrinsic affinities
and intrinsic enthalpies were obtained for the structure–thermo-
dynamics correlations.
Protonation pKa and enthalpy of CA–Zn
II-bound water
molecule of all 12 human CA isoforms
It is not straightforward to determine the pKa and the enthalpy of
protonation of the ZnII-bound hydroxide/water molecule.
Differently, from the compounds, it is not possible to pH-titrate
the protein and record with spectrophotometer or titration calo-
rimeter. Instead, in order to determine the pKa researchers have
determined the pH dependence of inhibition of enzymatic activity
or replaced Zn with Co that exhibited visible spectral changes
upon the change in pH. However, it is disputable to which extent
such non-natural CA represents the native CA.
In addition, we have determined the pKas of most CA isoforms
by fitting the inhibitor affinities at various pHs as explained ear-
lier in the discussion of U-shaped dependencies. The enthalpies of
protonation were determined via the global fit of the X-shaped
curves obtained by ITC titration of an inhibitor in two buffers.
Both the pKa and the enthalpy of protonation had to be obtained
only once with one inhibitor and then can be applied for other
inhibitors to obtain the intrinsic energetics of binding to a CA.
These data are summarized in Table 2 which shows the ther-
modynamic parameters of protonation of the hydroxide anion
bound to catalytically active CA isoforms. The pKas of human
CAs have been determined previously by using numerous tech-
niques, see the references in Table 2. Their values span between
approximately 6 and 8.5. The values determined by FTSA and
ITC were close to the values previously determined by other tech-
niques. However, there were several outliers of up to 1 pKa unit. It
seems that CA I and CA XIII have rather high pKas, above 8.0.
Remaining ones are essentially the same as determined previ-
ously. The standard deviation of combined FTSA and ITC deter-
minations in the pH dependencies described above do not exceed
0.2 pH or pKa units. This accuracy is highly dependent on the
correct calibration of the pH-meters and standard buffer prepara-
tions. The Gibbs energy changes upon protonation were recalcu-
lated according to Eq. (12). The enthalpies were the result of the
global fit of ITC titrations of each CA isoform with 1 at a series of
pH as explained above. The entropies were obtained by subtract-
ing the Gibbs energy changes from enthalpies (Eq. (3)). The
entropy values carry a largest standard deviation, a sum of devi-
ations of the enthalpy and Gibbs energy.
Determination of the pKa and the change of enthalpy of
protonation of the sulfonamide inhibitor amino group
Sulfonamide inhibitor amino group deprotonates with a pKa
between approximately 6 and 11. The actual value depends on
the chemical structure of the compound, the presence of
electron-withdrawing and donating groups, the size of the aro-
matic conjugated system and other factors. In order to calculate
the intrinsic parameters of these sulfonamide inhibitor binding
to CAs, it was necessary to determine the pKas and enthalpies
of their protonation.
The sulfonamide amino group pKa may be roughly estimated
from the proton NMR spectrum. The spectrum is determined for
every newly synthesized compound thus the information is readily
available. The chemical shift of the amino group protons corre-
lates approximately linearly with the spectrophotometrically mea-
sured pKa (Fig. 16).
To determine the pKa of the sulfonamide, the compound sol-
ution may be pH-titrated and the midpoint pH of the titration
would correspond to the pKa, as shown in Fig. 17 (Ladbury and
Doyle, 2004; Morkūnaitė et al., 2015). However, as shown by
the Whitesides group (Snyder et al., 2011), it is easier to deter-
mine the pKa by preparing the solution of the compound in a
series of buffers, made at 0.5 pH unit, and recording the UV spec-
trum of the solution at each pH. The spectrum changes around
the pKa and it is easy to find the wavelengths of the largest
change. The absorbance values at those pH are then used and
Fig. 12. ITC data of 1 binding to CA IX in two buffers at several pHs at 25 °C. The
observed enthalpies depended both on the buffer and on the pH used in the exper-
iment. In such cases, it is necessary to obtain the intrinsic enthalpy to perform any
meaningful Structure–Activity Relationship (SAR)-type study. The inset shows a typi-
cal ITC raw data curve.
Fig. 13. The observed enthalpies obtained by ITC of 1 binding to CA I in sodium phos-
phate or TRIS chloride buffer as a function of pH at 25 °C. Blue datapoints show the
ΔHobs in phosphate buffer, while black – in TRIS. Solid black and blue lines are global
fits to the above-described model (fit in the way where the pKas are consistent with
the FTSA data for each isoform) yielding the intrinsic enthalpy of binding (ΔHint, red
line) that is independent of pH. Dashed line shows a hypothetical situation how the
observed enthalpy dependence should look like if the enthalpy of buffer protonation
was equal to zero.
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plotted as a function of pH and normalized to the unit as shown
in Fig. 17a and c.
The enthalpies of sulfonamide amino group protonation may
be determined by titrating the compound solution with an acid
in an ITC calorimeter at a constant temperature. The compound
in a solid pure form exists as a protonated electrostatically neutral
sulfonamide. Therefore, it must be deprotonated by applying a
sufficient amount of base to achieve the pH sufficiently above
the pKa for accurate determination. We usually apply 50% surplus
of the base and therefore the resultant ITC curves appear as two-
step ITC reactions. Titration of such solution with a strong acid
provides a direct measurement of the enthalpy of protonation
as shown in Fig. 17d.
Alternatively, the enthalpy of protonation may be determined
by applying the van’t Hoff relationship and performing the pKa
determination at several temperatures as shown in Fig. 17e.
However, such determination is not as accurate as ITC because
it is assumed here that the enthalpy of protonation is independent
of temperature in the studied temperature range. To some extent
this assumption is correct, but the enthalpy is temperature-
dependent as seen from the ITC determinations at various tem-
peratures (Fig. 17f). There is a non-zero heat capacity associated
Fig. 14. ITC data of 1 binding to CA isoforms at 25 °C. Filled circles – ΔHobs determined in sodium phosphate buffer, open circles – ΔHobs determined in TRIS buffer,
dotted line shows value of ΔHint of 1 binding, solid curves are fits of experimental data, while the dashed curve is a fit of a hypothetical situation if there were no
buffer or the enthalpy of buffer protonation (ΔHpr,buf) was equal to zero. The fits were global with the FTSA U-shapes keeping the sulfonamide and CA pKas the
same. Experiments were performed in either 50 mM sodium phosphate or 50 mM TRIS chloride buffer containing 100 mM NaCl and up to 2% DMSO as previously
described in: CA I and CA II (Morkūnaitė et al., 2015), CA IV (Mickevičiūtė et al., 2017), CA VB (Kasiliauskaitė et al., 2016), CA VI (Kazokaitė et al., 2015), CA VII
(Pilipuitytė and Matulis, 2015), CA IX (Linkuvienė et al., 2016b), CA XII (Jogaitė et al., 2013), CA XIII (Baranauskienė and Matulis, 2012). All panels are drawn at
the same scale to help visualize the differences in enthalpies of binding. No data has been determined at comparable conditions for CA III, CA VA, and CA XIV.
The overall pattern of the X-shapes is similar, but details are different due to different pKa,CA and ΔHint for each isoform.
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with the protonation process. The heat capacity change upon pro-
tonation is positive (Matulis and Todd, 2004; Morkūnaitė et al.,
2015) as usually is the case of ionic binding reactions.
Why intrinsic data is necessary for making compound
structure–thermodynamics correlations
It is often thought that it is sufficient to make a SAR-type analysis
based on the observed data. This may be true to some extent when
the compounds are very similar and there is no need to make
explanations why one or another compound binds stronger or
weaker to a particular protein. However, if we would like to
understand the physico-chemical reasons behind the observed
thermodynamic parameters, e.g., determine the contributions of
particular atoms to the binding energetics, it is necessary to oper-
ate with the intrinsic parameters.
Figure 18 shows the observed and intrinsic Kds for a series of
compound binding to human CA VI. The compounds were
arranged in the order of decreasing intrinsic affinity. It is clear
that the intrinsic and observed affinities do not correlate for
these compounds. The observed Kd for the first and last com-
pound in the figure are almost the same, but the intrinsic affinities
differ by more than 300 fold. Not knowing the intrinsic values
would yield completely wrong conclusions about the structural
determinants of the compounds that cause the affinity to be
greater or smaller.
Another example (Fig. 19) shows a different situation when the
observed binding constants are quite different, but the intrinsic
ones are nearly the same. If only the observed data were available,
one could make an erroneous conclusion that fluorines substan-
tially increase the affinity of the compound towards CA I due to
the contacts between fluorines and the protein. However, in actual-
ity, fluorines increase the affinity by only 1.5-fold (equal to the ratio
of the intrinsic binding constants) due to direct contacts and the
remaining 100-fold increase in the observed affinity arises simply
due to the reduction of the pKa of the sulfonamide amino group
by electron-withdrawing capabilities of the fluorine atoms.
Intrinsic kinetics of sulfonamide inhibitor interaction with
the CAs
It has been shown that sulfonamide inhibitors bind CAs with an
unusually slow association kinetics, too slow to be explained by a
diffusion-limited association (Linkuvienė et al., 2016b). We have
performed the kinetic measurements as a function of pH and
showed that the apparent discrepancy may be explained by the
application of the same model that was applied to determine
the intrinsic thermodynamic parameters of binding (Linkuvienė
et al., 2018). After the correction of the association rates by the
available fractions of the binding-ready deprotonated sulfon-
amides, the rates appeared to be much more consistent with the
diffusion-limited single-step kinetics.
The kinetics of sulfonamide association was determined by
SPR. Typical data are shown in Fig. 20. The dependence of the
association rates on pH (Fig. 21) shows that the rates exhibit an
upside U-shape and may be explained by the fractions of available
deprotonated sulfonamide and protonated CA. The intrinsic asso-
ciation rate ka,int is pH-independent but almost never observed
experimentally because the fractions are much lower than
1. Contrary, the dissociation rates kd,int appear to be independent
of pH as expected for a simple 1 : 1 binding case. Therefore, the
intrinsic dissociation rates could be observed experimentally
directly by SPR.
The model explaining the pH kinetic data is presented in
Fig. 22. The linked protonation-deprotonation reactions explain
the apparently slow interaction kinetics. Figure 23 shows two
association rates for the same compound, but one dissociation
rate. The two association rates are connected by a vertical line.
The upper point represents an intrinsic association rate that
would be observed under such hypothetical conditions when
the fractions of both interacting species are equal to 1. The
lower point is the experimentally observed association rate.
The most interesting, strongest-binding compounds were very
slow-dissociating ones. Their residence times were approximately
equal to several hours and could not be directly determined by
SPR. However, they could be estimated from the association
rates and the thermodynamic binding constant, available from
the equilibrium measurements by FTSA. The position of such
compounds is shown in the shaded gray area on the left side of
Fig. 23. The residence times of the lead binding compounds for
several CA isoforms appear to be in the order of 3–6 h.
The kinetic measurements have further confirmed the mecha-
nism of sulfonamide inhibitor binding to CAs and further vali-
dated the necessity to determine the intrinsic binding data, not
only observed.
A database of intrinsic affinities of sulfonamide inhibitor
binding to all 12 catalytically active human CAs
In Supplementary Table 1, we have assembled a database of 402
primary sulfonamide compounds binding to the 12 catalytically
active human CA isoforms. There is limited data in the literature
where the intrinsic parameters of interaction have been consid-
ered. Major efforts to assemble and analyze sulfonamide–CA
interaction intrinsic data have been made by the G. Whitesides
laboratory (Krishnamurthy et al., 2008), however, only for one
CA isoform, CA II, and thus did not provide information on com-
pound isoform-selectivity. The synthesis, purification, and charac-
terization of chemical compounds 9–402, except 303, presented
in Supplementary Table 1 have been previously described by
Fig. 15. The enthalpy changes upon compound 303 binding to CA XIII at various pHs.
The curve was fit using the following parameters: pKa,SA = 6.25, pKa,CA = 8.3, ΔHint =
−37 kJ mol−1 , ΔHpr,SA =−28 kJ mol−1 , ΔHpr,CA =−40 kJ mol−1. The open and closed
symbols show the data obtained by two independent researchers. The solid curve
matched the data resembling all bends in the curve except the discrepancy in the
alkaline region. Possibly the protein is slightly destabilized in this region. The hori-
zontal straight line shows the change in the intrinsic enthalpy upon binding if we
assume that the reaction occurs according to Eq. (7). However, the same indistin-
guishable curve would be obtained for Eq. (4) and Eq. (7). The intrinsic enthalpy
would then be different. The thermodynamic data alone cannot distinguish the mod-
els and we base our decision that Eq. (7) is correct based on crystallographic data.
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Table 2. Thermodynamic parameters of protonation of CA-ZnII-bound hydroxide anion (Eq. (8), third reaction) for all 12 catalytically active CA isoforms. The pKa values determined by various methods and taken from
the earlier literature are listed in the second column together with the references. Other values were determined by FTSA and ITC with the references listed in the first column next to the CA isoforms. The uncertainty of
the pKa values determined by FTSA and ITC is approximately 0.2 pH units, while for the change in Gibbs energies and enthalpies it is approximately 2 kJ mol
−1
CA isoform pKa,CA
pKa,CA ΔGpr,CA (kJ mol
−1) ΔHpr,CA (kJ mol
−1) TΔSpr,CA (kJ mol
−1)
25 °C 37 °C 25 °C 37 °C 25 °C 37 °C 25 °C 37 °C
Technique - Inhibition FTSA, ITC
CA I (Morkūnaitė et al., 2015) 8.1 (Coleman, 1967) 8.4 ± 0.2 8.1 −47.9 −48.2 −41.0 −38.5 6.9 9.7
6.9 (Innocenti et al., 2009)
7.1 (Engstrand et al., 1995)
7.3 (Whitney and Brandt, 1976; Khalifah, 1977;
Khalifah et al., 1977)
CA II (Morkūnaitė et al., 2015) 6.9 (Duda et al., 2001; Mikulski et al., 2011a) 7.1 6.9 −40.5 −41.1 −26.0 −23.5 14.5 17.6
7.1 (Innocenti et al., 2009)
6.8 (Tu et al., 2002)
CA III ∼5 (Tu et al., 2002) 6.6 6.5 −37.7 −38.6 ND ND ND ND
∼5 (Jewell et al., 1991; Qian et al., 1997)
<6 (Elder et al., 2007)
Escherichia coli CA IV (Mickevičiūtė et al., 2017) 6.2 (Baird et al., 1997) 6.8 6.6 −38.8 −39.0 −33.0 −30.5 5.8 8.5
Murine CA IV 6.6 (Hurt et al., 1997)
CA VA ND 7.3 7.3 −41.7 −43.3 ND ND ND ND
CA VB (Kasiliauskaitė et al., 2016) ND 7.2 7.0 −41.1 −41.5 −30.0 −27.5 11.1 14.0
E. coli CA VI (Kazokaitė et al., 2015) ND 6.2 6.0 −35.4 −35.6 −32.0 −29.0 3.4 6.6
Saliva CA VI (Kazokaitė et al., 2015) 5.5 −31.4
Mammalian CAVI (Kazokaitė et al., 2015) 5.5 −31.4
CA VII (Pilipuitytė and Matulis, 2015) 7.0 6.8 −40.0 −40.2 −33.0 −30.5 7.0 9.7
Murine CA VII 6.2 (Earnhardt et al., 1998)
CA IX (Linkuvienė et al., 2016b) 6.3 (Wingo et al., 2001) 6.8 6.6 −38.8 −39.4 −24.0 −21.5 14.8 17.9
cdCA IX (catalytic domain) 7.01 (Innocenti et al., 2009)
CA IX (full length) 6.49 (Innocenti et al., 2009)
CA XII (Jogaitė et al., 2013) 7.1 (Ulmasov et al., 2000) 7.0 6.8 −40.0 −40.4 −28.0 −25.5 12.0 14.9
6.9 (Innocenti et al., 2009)
CA XIII (Baranauskienė and Matulis, 2012) ND 8.3 8.0 −47.4 −47.5 −44.0 −41.5 3.4 6.0
CA XIV (Juozapaitienė et al., 2016) 6.92 (Innocenti et al., 2009) 6.8 6.8 −38.8 −40.4 ND ND ND ND
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Dudutiene et al. (2007); Baranauskienė et al. (2010); Čapkauskaitė
et al. (2010, 2012, 2013, 2017); Sūdžius et al. (2010); Dudutienė
et al. (2013, 2014, 2015); Kišonaitė et al. (2014); Morkūnaitė
et al. (2014, 2015); Rutkauskas et al. (2014, 2017); Zubrienė
et al. (2014, 2015, 2017); Kazokaitė et al. (2015); Pilipuitytė and
Matulis (2015); Juozapaitienė et al. (2016); Kasiliauskaitė et al.
(2016); Linkuvienė et al. (2016b); Mickevičiūtė et al. (2017);
Vaškevičienė et al. (2017). The other compounds were purchased
from Sigma-Aldrich Chemical Co. and used without further
purification.
Instant JChem was used for structure database management,
search and prediction, Instant JChem 6.1.3, 2013, ChemAxon
(http://www.chemaxon.com).
A database of intrinsic enthalpies and entropies of
sulfonamide inhibitor binding to all 12 catalytically active
human CAs
In Supplementary Table 2, we put together available data on the
intrinsic enthalpies and entropies of primary sulfonamide binding
to human CAs. The table lists the intrinsic Gibbs energies, enthal-
pies, and entropies of binding together with the experimentally
determined (or estimated) pKas of the sulfonamide amino
group of the compounds. These listed pKas were used to calculate
the intrinsic parameters of binding as explained in the previous
sections.
The observed and intrinsic binding affinity data in Supplementary
Table 1 and the intrinsic enthalpy–entropy data in Supplementary
Table 2 needs detailed analysis and we hope that it will be useful
for computational chemists who are designing in silico binding
models that would enable prediction of binding thermodynamic
parameters.
Some analysis of the compound affinity and selectivity towards
each CA isoform has been provided in the references. However,
the much deeper analysis may be performed. Here, we concen-
trate on the most general observations and structure–thermody-
namics correlations.
The intrinsic enthalpies and entropies were plotted on a
so-called enthalpy–entropy compensation plot (Chodera and
Mobley, 2013; Ahmad et al., 2015; Dragan et al., 2017) and
shown in Fig. 24. The plot is drawn as a square with the same
enthalpy and entropy scale spreading from compounds that exhibit
high exothermic enthalpy to compounds that are fully entropy-
driven. Diagonal lines represent isoaffinity areas. Most compounds
in this study are bound with an intrinsic affinity (kd,int) between
10 µM and 1 pM. The intrinsic Gibbs energies of binding spread
from approximately −40 kJ mol−1 to −70 kJ mol−1. However, the
ranges of enthalpies and entropies were significantly larger. The
enthalpies spread from −90 kJ mol−1 to 10 kJ mol−1 while entro-
pies – from −50 kJ mol−1 to 20 kJ mol−1.
The thermodynamic parameters to various CA isoforms
tended to assemble in groups. For example, CA I bound ligands
with highly exothermic enthalpy and near-zero entropy, while
CA IX bound compounds with only slightly exothermic enthalpy
and a significant positive entropy contribution. Thus CA I bound
ligands due to primarily enthalpic reasons, while CA IX binding
was dominated by the positive entropy contribution. This effect
is puzzling and the exact values most likely depend on exact posi-
tions of water molecules at the protein–ligand surface prior and
post-binding.
We took great care to ensure as high precision of the data as
possible. The standard deviation, uncertainty, repeatability, and
precision of FTSA measurements have been discussed in
Cimmperman and Matulis (2011) and ITC (Linkuvienė et al.,
2016a). Several orthogonal methods have been used where possi-
ble to ensure as precise data as possible. However, the standard
deviation of all methods for all thermodynamic parameters,
including Gibbs energies, enthalpies, and entropies, essentially
cannot be reduced below approximately ± 1 kJ mol−1.
Therefore, the precision of the data should not be overstated.
For example, if the affinities (Kd) of two compounds differ by
2-fold it means that the values are within the error margin and
it is insufficient data to reliably conclude which compound is a
stronger binder. Similar precision could be applied for enthalpies
and entropies.
Recombinant preparation and characterization of the
human CAs
The quality of prepared CA proteins
All 12 catalytically active human CA isoforms have been prepared
in our laboratory. There was always of a concern how pure those
preparations are and whether the preparations exhibit a specific
activity that is comparable with the proteins described in the
literature.
The proteins have been confirmed by such standard tech-
niques and SDS-PAGE and high-resolution mass spectrometry.
They were of correct molecular weight on resolving gels and
exhibited a mass that was within a single Da from the mass pre-
dicted from the amino acid sequence. However, we think that in
addition, it is of most importance to demonstrate that the entire
protein preparation is catalytically active by titrating it with an
inhibitor and thus demonstrate that the entire preparation of
the protein is catalytically active and it is not contaminated by
non-active fraction of the same protein that may be indistinguish-
able by other techniques.
Figure 25 shows the activity titration of CA XIV. First, it is nec-
essary to titrate the active fraction of the protein. The known large
concentration of CA XIV, 500 nM, was added to the solution and
various concentrations of a strongly-binding inhibitor 1 were
Fig. 16. Correlation between the pKas of sulfonamide amino group (determined spec-
trophotometrically) and the chemical shift of the sulfonamide amino group protons
as determined by NMR in deuterated DMSO solvent. Three series of compounds are
distinguished in three colors and symbol shapes, VD series are mostly fluorinated
benzenesulfonamides, EA and E series are mostly chlorinated compounds. The cor-
relation is approximately linear. The plot may be used to obtain an estimate of the
amino group pKa from proton NMR data when characterizing newly synthesized pri-
mary sulfonamides.
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added. Two straight lines should intersect at exactly 500 nM as
was experimentally observed (Fig. 25) if the inhibitor is of suffi-
cient binding affinity.
Protein purity can be further confirmed by demonstrating
inhibition by several known inhibitors. Then, it is useful to dem-
onstrate using a strong inhibitor that the compound binding stoi-
chiometry by ITC is near 1. Determination of the protein stability
in various buffers and various compounds that are known binders
is also useful. Finally, X-ray crystallographic structural character-
ization of the protein is one of the most widely accepted tech-
niques to show that the protein is of high purity. All these
techniques are orthogonal and complementary and add to the
overall picture that we need in order to understand the struc-
ture–thermodynamics of protein–ligand binding.
The recombinant CAs may not be fully representative of their
behavior in live human cells. First, here we produced only the cat-
alytic domains of isoforms that contain transmembrane domains
(CA IX, CA XII, and CA XIV). The dimerization of these and
other isoforms may also be affected thus changing the compound
affinities. Furthermore, different isoforms may be posttranslation-
ally modified in human and not represented in bacterial prepara-
tions. Therefore, despite the recombinant proteins being the best
models representing proteins in the human body, it should be
used with some caution.
However, for several monomeric isoforms that were produced
in bacteria in full length and where no glycosylation or other post-
translational modifications are known, the bacterial recombinant
isoforms are an excellent model to represent their binding of a
potential drug in the human body.
The most interesting and compelling case is of CA VI which
can be affinity-purified from human volunteer saliva. We have
demonstrated that the CA VI preparations from human saliva
and the protein recombinantly prepared from mammalian cells,
as previously described by Kazokaitė et al. (2015), exhibited
essentially the same affinity towards a large series of sulfonamide
compounds (Fig. 26).
Thermal stability of CA isoforms
Figure 27 shows the thermal stabilities of all 12 catalytically active
CA isoforms in various buffers as a function of pH. The stability
profiles are quite similar among the isoforms, with stability max-
imal and minimal pH dependence between pH 6 and 9. Isoform
CA VI is somewhat exceptional with the pH stability maximum
Fig. 17. Determination of the pKa and enthalpy of protonation (ΔHpr,SA) of the sulfonamide amino group. Left panels (a), (c), and (e) show the spectrophotometric,
while right panels (b), (d), and (f) show the ITC data. (a) UV-Vis spectra of the compound solution in buffers of various pH. (c) The normalized absorbance change at
a chosen wavelength or ratio of two wavelengths. (e) Determination of the ΔHpr,SA via van’t Hoff relationship, the dependence of the pKa on temperature. (b) ITC raw
data of titrating a base-neutralized (with 1.5 equiv.) sulfonamide with HNO3. (d) Integrated ITC curves of the sulfonamide titration with acid. ( f) Determination of
the heat capacity of protonation by performing the ITC titrations at various temperatures. The ΔCp values for 310 and 369 were equal to 107 J mol
−1 K−1 and 88 J
mol−1 K−1, respectively.
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between pH 5 and 6. The most stable isoform is CA IX, the next is
CA IV, while CA VII and CA XII are the least stable isoforms. It
should be kept in mind that these are stabilities of catalytic
domains and may not fully represent native CAs that contain
transmembrane parts.
Interestingly, the citrate bufferexhibits a strongdestabilizing effect
onmost CA isoforms, most likely because citrate binds ZnII and thus
destabilizes CAs by pulling the metal cation from the active site.
X-Ray crystallographic studies of human CA isoforms
In this section, the X-ray and neutron crystallographic structures
of human recombinant unliganded CA isoforms and with bound
ligands in the active site are reviewed that were deposited to the
PDB up to the Fall of 2017. First, we concentrate on the apo-
protein and later review the ligand binding studies.
CA I
The very first crystal structure of CA reported as the human
erythrocyte CA form B, was the structure of CA I (Kannan
et al., 1975). The crystallization report appeared earlier (Kannan
et al., 1972a) and the structure was revisited and refined to the
resolution of 2 Å (Kannan et al., 1984). The bicarbonate in CA
I was found as a monodentate ligand in the tetrahedral coordina-
tion sphere of Zn ligands (Kumar and Kannan, 1994). This posi-
tion differs from that in the crystal structure of CA II-Co-HCO−3
complex, where cobalt substitutes for the zinc (Haakansson and
Wehnert, 1992). In this structure, the bidentate binding of
HCO−3 was found. Further crystal structures of CA I with anionic
inhibitors (Kumar et al., 1994) revealed differences in the binding
of two anions: iodide replaced the Zn-bound water, whereas gold
cyanide did not bind to the zinc directly. One of CN− atoms made
H-bond with the Zn-bound water. Thus, Au(CN)2− can inhibit
CA I because it occupies a substrate binding site, whereas I−
directly binds to Zn.
An interesting naturally occurring genetic variant of CA I,
Michigan 1(Ferraroni et al., 2002), where His67 residue is
replaced with Arg, could bind an additional zinc ion. An addi-
tional Zn-binding site was formed by His64, His200 and Arg67
side chains. Coordination of ZnII by arginine side chain is rare.
CA II
Crystallographic studies of CA II play a very important role in the
field of human CAs. First CA II structure was described in 1972
(Kannan et al., 1972b; Liljas et al., 1972) as the human erythrocyte
CA form C. First CA II crystal structures of limited resolution 2 Å
were obtained by Liljas et al. (1972) as early as in 1972 (Liljas
et al., 1972), then revisited and refined in 1988 (Eriksson et al.,
1988a). Additional restrained refinement allowed to identify
water molecules in the active site, one of them bound to the
ZnII. The structure helped to elucidate the reaction mechanism.
High-resolution crystal structures of CA II appeared later and
helped to understand the water network in the active site
(Fisher et al., 2007a; Avvaru et al., 2010b). There was also some
variability in crystal forms of CA II, first mentioned by Robbins
et al. (2010).
Coordination of Zn
Numerous mutational studies were attempted in order to modify
the tetrahedral coordination sphere of ZnII that in α-class CAs is
formed by three histidine side chains and a water molecule as a
Fig. 18. The observed and intrinsic Kd of a series of sulfonamide compound interac-
tion with CA VI (Kazokaitė et al., 2015). There is clearly no correlation between the
observed and intrinsic binding affinities.
Fig. 19. The observed and intrinsic Kd of two sulfonamide compound interaction with
CA I. The compounds are para-substituted benzenesulfonamides, one of them with
four fluorines on the benzene ring. The observed affinity showed that the
F-bearing compound bound CA I significantly stronger than the non-fluorinated com-
pound. The intrinsic Kds were practically equal for both compounds, but the
observed ones differed by 150-fold mostly due to the reduction of the pKa of the fluo-
rinated compound and not direct recognition between the F atoms and the protein
surface.
Fig. 20. An example of raw SPR data. Interaction of 368 with CA II at pH 8.0 as
described by Linkuvienė et al. (2018). The data are shown in black while the globally
fitted curves – in red. Each consecutive curve was obtained at a half concentration of
the compound as compared with the previous one.
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fourth ligand. The crystal structure of Zn-free CA II was first
described in 1992 (Haakansson et al., 1992), the water network
was compared with CA II at different pH with inorganic ligands.
Removal of ZnII has an influence on the protein stability and flex-
ibility as shown by Avvaru et al. (2009), but not much effect was
observed on substrate binding (Domsic et al., 2008).
The mutation of Zn-binding histidine (His94) to aspartate side
chain (Kiefer et al., 1993) reduced the affinity to the metal and the
catalytic activity of CA II. When the same residue His94 was
replaced by cysteine side chain (Alexander et al., 1993), no zinc
was found in the crystal structure of the mutant. On the other
hand, replacement of two Zn-coordinating residues His94 and
His119 by asparagine and glutamine side chains (Lesburg et al.,
1997) resulted in an active enzyme, albeit the crystal structures
of these mutants revealed the distorted geometry of ZnII ligands.
The effects of Zn-binding histidine replacements by cysteine and
aspartate side chains were described by Ippolito and Christianson
(1994), though the crystal structures are of limited resolution
(2.2–2.4 Å).
Mutation of Thr199 side chain to cysteine was performed as an
attempt to modify the metal-binding site (Ippolito and
Christianson, 1993). The measured affinity to ZnII was increased,
cysteine side chain displaced Zn-bound water, reducing the
catalytic activity of the mutant. The mutation of Thr199 to hydro-
phobic valine (Krebs et al., 1993) led to the conclusion that
Thr199 is important in the formation of H-bond to the transition
state and van der Waals contacts with HCO−3 . Femtomolar affin-
ity to zinc was achieved by Thr199 replacement with aspartate
(Ippolito et al., 1995). Mutational studies of residues Thr199
and Glu106 (Xue et al., 1993a) revealed the dependence of the
catalytic activity on the direction of H-bond between residues
199 and 106.
The effect of Zn replacement by other metals was also studied
in detail (Haakansson and Wehnert, 1992; Haakansson et al.,
1994b). A study could be mentioned, where Co-CA II was used
for the enhancement of the pH effect on the visible spectra
(Avvaru et al., 2010a). The effect of high ionic strength and espe-
cially of citrate anion used in crystallization was discussed and the
crystal structures revealed changes in the coordination sphere of
Co due to pH variation.
The ‘secondary coordination sphere’ of zinc has an effect on
the stability of the Zn-binding by histidines (Lesburg and
Christianson, 1995; Huang et al., 1996). Mutations in the ‘second-
ary coordination sphere’ do not distort significantly the protein
conformation, but changing of H-bond network around
Zn-binding histidines has an effect on the affinity to metal
(Q117E mutant has higher affinity to ZnII) and on the ‘fine tun-
ing’ of the pKa of the Zn-bound water. A comprehensive muta-
tional study (Cox et al., 2000) where mutations of several
hydrophobic residues forming the ‘secondary coordination
sphere’ influenced the affinity of CA II to metal ions has demon-
strated that the protein can accommodate large changes in the
hydrophobic core, but the optimized geometry of ZnII ligation
is distorted by these mutations.
The importance of the metal coordinating residues was summa-
rized in the review (Martin et al., 2013). Mutants H94C and H94D
were compared with the WT enzyme while screening small mole-
cule inhibitors. The crystal structures of the mutants soaked with
benzenesulfonamide and 1-hydroxy-2-sulfanylpyridinium that rep-
resents another metal-binding group are compared.
Proton transfer
After noticing the flexible conformation of the His64 side chain
(Krebs et al., 1991; Nair and Christianson, 1991) at different
pH, the proton transfer pathway was proposed and confirmed
analyzing numerous mutants of CA II by McKenna and
Christianson groups (Nair and Christianson, 1991; Scolnick and
Christianson, 1996; Tu et al., 2002; Bhatt et al., 2005, Fisher
et al., 2005; Zheng et al., 2008; Domsic et al., 2010; Mikulski
et al., 2011a, 2011b, 2013).
Fig. 21. The dependence of observed ka (left graph) and
observed kd (right graph) on pH at 25 °C. It is obvious, as
previously observed by Taylor et al. (1970), that the
on-rate ka depends on pH in a similar fashion as the
thermodynamic KD. However, the dissociation rate kd
is independent of pH as shown on the right graph
drawn at the same scale as the left one.
Fig. 22. The model of linked reactions, similar to the model explaining the intrinsic
thermodynamics described above, that explains the pH dependence of the associa-
tion rate. The observed association rate depends on pH while the observed dissoci-
ation rate is independent of pH and thus is equal to the intrinsic dissociation rate.
The intrinsic association rates may be calculated applying the same equations
describing the fractions of binding-ready species as in the thermodynamic calcula-
tions above.
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Proton transfer pathway studies were greatly enhanced by neu-
tron diffraction crystallography that can visualize deuterium. In
the case of CA II, very large crystals of a very good quality
could be grown, that made it possible to collect neutron diffrac-
tion datasets. Crystals were also stable enough to survive soaking
in D2O-based solution in order to exchange labile protons for
deuterium (Budayova-Spano et al., 2006). Results from
McKenna group involved in this study shed more light on the
protonation state of the catalytically important residues (Fisher
et al., 2010, 2011, 2012a; Michalczyk et al., 2015).
Substrate binding
The binding of HCO−3 was for the first time observed in the
T200H mutant of CA II (Xue et al., 1993b). The bicarbonate
was bound as a bidentate ligand in the active site of this mutant,
that has an increased affinity for HCO−3 . Bicarbonate ion was
found also in several crystal structures of CA I (Kumar and
Kannan, 1994) and CA II (Haakansson and Wehnert, 1992;
Xue et al., 1993a, 1993b; Huang et al., 2002), whereas the binding
of CO2 at the active site of CA II (WT and Zn-free) was described
in the crystals pressured with CO2 (Domsic et al., 2008). The
interconversion of CO2 into bicarbonate was also directly
observed at 100 K (Sjöblom et al., 2009).
The comparison of acetate binding by CA II, WT as well as
Q106E mutant, helped to understand the H-bond network
Glu106-Thr199 (Haakansson et al., 1994a). The role of hydro-
phobic residues in substrate binding site was elucidated by the
mutational analysis of CA II residues Val121 (Nair et al., 1991)
and Val143 (Alexander et al., 1991). In order to clarify the role
of the main chain amino group of Thr199, the crystal structures
of the double mutant T199P/C206S with small ligands were ana-
lyzed (Huang et al., 2002). Substitutions of the Leu198 side chain
had an effect on substrate binding and catalytic activity (Nair and
Christianson, 1993; Nair et al., 1995). Mutations of residues
Asp75 and Gln74 were also investigated (Kannan, 1981).
CA III
The structural studies of CA III isoform were begun, most prob-
ably, by the crystallization of the reduced bovine CA III from red
Fig. 23. Association-dissociation rates for a series of
compound interaction with several CA isoforms. Each
compound-CA interaction is described by two points
connected by a vertical line. The upper point describes
the intrinsic ka and the lower point describes the
observed ka. The dissociation rate kd is the same,
observed or intrinsic, therefore there is only one point
on the horizontal axis. Observed ka and kd values in
the right side of the graph were obtained using SPR,
while kds in the grey-shaded area could not be deter-
mined with the desired precision by SPR and thus
were calculated using KD obtained by FTSA and ka
obtained by SPR. The leftmost three compounds exhibit
extremely slow dissociation and their residence times
are in the order of several hours. Dashed diagonal
lines represent isoaffinity lines with the thermodynamic
Kd values listed above and on the right side of the graph.
Different colors and symbol shapes represent com-
pound binding kinetic parameters to several CA
isoforms.
Fig. 24. The enthalpy–entropy compensation plot for all inhibitors listed in
Supplementary Table 2. Different colors and symbol shapes represent binding data
to various CA isoforms. Most compounds bound to CAs both due to favorable enthal-
pies and favorable entropy contributions. However, there were few that bound with
enthalpy-opposed and entropy-opposed thermodynamics. Note that despite signifi-
cant differences in compound chemical structures, the values grouped according to
CA isoform: CA I binders were mostly on the top-left corner while CA IX – on the right-
lower part of the plot.
Fig. 25. Determination of the catalytically active fraction of the preparation of CA XIV
as previously described by Juozapaitienė et al. (2016), performed according to
Copeland (2005). Two straight lines intersected at exactly 500 nM concentration
equal to the added concentration of CA XIV thus confirming that the entire prepara-
tion of CA XIV was enzymatically active. The inset shows the decrease in absorbance
lines at various inhibitor concentrations (steep blue lines – no inhibitor, shallow red
lines – largest inhibitor concentration added). The red CO2 curve shows spontaneous
hydration of CO2 in the absence of enzyme.
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muscle (Eriksson and Liljas, 1993). The S-glutathionated form of
the rat liver enzyme was also described (Mallis et al., 2000). Two
surface cysteines, Cys183 and Cys188, were modified and the sig-
nificance of this modification in the oxidative stress was discussed.
The mechanism of proton transfer by human CA III was eluci-
dated in mutational and structural studies (Duda et al., 2002, 2005).
The replacement of Phe198 side chain by leucine has increased the
catalytic activity of CA III. An interesting feature of the CA III crystal
structures is the ordered C-terminal His-tag that is bound in the
active site cavity of the crystallographic symmetry-related subunit.
In the WT enzyme, there is a stacking between one of the
Zn-coordinating histidines and the phenyl group of Phe198. The
possible mechanism of proton donor activation is discussed (Duda
et al., 2005). The role of Lys64 and Arg67 side chains, which are
the structural analogs of CA II His64 and Asn67, respectively, in
the proton transfer was attempted to clarify (Elder et al., 2007).
CA IV
The first crystal structure of the membrane-associated CA IV was
reported by Stams et al. (1996). The soluble secreted mutant of
CA IV with the C-terminal deletion was crystallized with a limited
resolution. The conformation of the N-terminal domain was sta-
bilized by two disulfide bonds: Cys6–Cys11 and Cys23–Cys203.
The crystal structures of murine CA IV (also a truncated form)
were solved by the same group later and compared with CA II
(Stams et al., 1998). The protein contains intramolecular disulfide
bond typical for trans-membrane and secreted CAs (Cys23–
Cys203 in CA I) (Stams et al., 1996). The N-terminal insertion
of 5 amino acids in the murine CA IV was compared with
other CAs (Stams et al., 1996, 1998).
CA VI
In the only published crystal structure of the catalytic domain of
CA VI (Pilka et al., 2012) the intramolecular disulfide bond
(Cys42–Cys224) was also found. Such disulfide bonds are typical
in membrane-bound CA IV, CA XII, and CA XIV. It is interesting
that the octahedrally coordinated MgII was found in the active site
instead of ZnII. The NCS dimer was found in the crystal structure
and both active sites face each other, differently from CA IX and
CA XII. His85 in this structure is a good candidate for the proton
shuttle.
CA VII
There are two crystal structures of CAVII found in the PDB data-
base: the unpublished complex with ethoxzolamide 1 (PDB ID:
3MDZ) and the complex with acetazolamide 2 (Fiore et al.,
2010a). The mutant with two cysteine residues replaced with ser-
ine side chains was used in the crystallization. Intramolecular
disulfide bond was found in the crystal (Cys54–Cys178), but
authors argued that it is an artifact, because no conserved homol-
ogous disulfide was found and such bonds are rare in the cytosolic
proteins. 2 makes H-bonds with the protein main chain atoms,
water molecules, Gln92 side chain, and van der Waals contacts
with the Phe131 side chain.
CA VIII (Carbonic Anhydrase Related Protein, CARP)
The crystal structure of the only structurally characterized CARP,
CAVIII, was solved in 2009 (Picaud et al., 2009). The CARP pro-
teins lost their catalytic activity because Zn-coordinating residue
His94 (CA II numbering) is replaced by Arg116. The
N-terminal Glutamine-rich loop (residues 24–36), a peculiar fea-
ture of CA VIII, is partially resolved in the structure. This loop
forms contacts with another unique feature of CA VIII, an α3
− β15 loop. Both structural elements contribute to the relatively
negatively charged surface of the protein. Two bulky residues
restrain a cavity near the active site (Arg116 and Ile224) (homol-
ogous to Thr200 of CA II). The residue Glu114 replaces in CA
VIII the CA II residue Gln92. Substitutions of the active site res-
idues by more bulky side chains probably preclude the binding of
CO2. Chloride anion is modeled in the crystal structure instead of
zinc.
CA IX
The structure of Fab fragment of anti-CA IX mAb M75 with the
peptide representing epitope, the proteoglycan-like (PG) segment
of CA IX was described (Kral et al., 2008) and the problems of
epitope recognition by the antibody are discussed. The first crystal
structure of the catalytic domain of CA IX with bound AZM drug
appeared in Alterio et al. (2009). The protein was produced using
the Baculovirus expression system. The residue Cys41, responsible
for intermolecular disulfide bond, that stabilizes a dimer, was
replaced by serine. The dimerization interface differs from that
of CA XII. Active sites of monomers are located on the same
side of the dimer. AZM makes several H-bonds with side chains
Thr199-200 and Gln92.
Crystallization of CA IX even with a published structure in
view, was not an easy task, but finally, it was solved (Leitans
et al., 2015). The protein was expressed in yeast and the binding
of a series of 2-thiophene-sulfonamide compounds to CA IX was
characterized structurally. Binding of one ligand by CA IX was
compared with CA II (Leitans et al., 2013). The tail part of thio-
phenes interacts with the side chain of Phe131 in CA II, that cor-
responds to the Val130 in CA IX. The presence of phenylalanine
Fig. 26. Correlation between observed inhibitor binding affinities to CA VI produced
by three different paths (Kazokaitė et al., 2015). Human recombinant CA VI was pre-
pared in bacterial and mammalian cell cultures. The native human CA VI was also
affinity-purified from human volunteer saliva. Comparing the affinities of the com-
pounds to the three kinds of CA VI we see that affinities are highly similar and iden-
tical within an error margin with the exception of bacterial preparation that bound
the compounds with systematically higher affinity by approximately 2–3 fold. This dif-
ference could be caused by the different dimerization pattern of various CA VI
preparations.
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in CA II is the main reason for the differences in the binding
mode.
CA XII
The first crystal structures of CA XII and CA XII-AZM complex
were reported in 2001 (Whittington et al., 2001). In the first struc-
ture, acetate ion is present as the fifth ligand of zinc. Its position
mimics the binding of bicarbonate. AZM is bound in the other
structure of CA XII. As in CA II, AZM interacts with a Phe131
side chain, that is absent in CA XII, the position of ligand
differs between two isoforms. CA XII was used for the compari-
son of binding of various compounds with different human
CA isoforms in the search of isoform-specific inhibitors
(Čapkauskaitė et al., 2013; Dudutienė et al., 2013, 2014, 2015;
Zubrienė et al., 2015).
CA XIII
The first published structures of CA XIII contained acetate and
AZM bound in the active site (Fiore et al., 2009). In the structure
with acetate, the zinc is penta-coordinated (with acetate and water
molecule). The other structure contains 2. No H-bonds with 2
were evident in the structure. Recently several series of
benzenesulfonamide-based inhibitors were analyzed bound
in CA XIII in the search for isoform-specific ligands
(Čapkauskaitė et al., 2013; Dudutienė et al., 2013, 2015;
Kišonaitė et al., 2014).
Fig. 27. Characterization of CA isoform stability in various buffers at various pHs. The isoform stability profiles look similar with the greatest stability near pH 7, but
there are several notable exceptions, especially CA VI that exhibits stability maximum around slightly acidic pH 5. Note that citrate buffer is destabilizing all CAs
because it is complexating ZnII and thus destabilizing the native conformation of CA. Experiments were performed in 100 mM buffer containing 2 mM NaCl and 0.5%
DMSO as previously described in: CA I and CA II (Morkūnaitė et al., 2015), CA IV (Mickevičiūtė et al., 2017), CA VB (Kasiliauskaitė et al., 2016), CA VI (Kazokaitė et al.,
2015), CA VII (Pilipuitytė and Matulis, 2015), CA IX (Linkuvienė et al., 2016b), CA XII (Jogaitė et al., 2013), CA XIII (Baranauskienė and Matulis, 2012), and CA XIV
(Juozapaitienė et al., 2016). All panels are drawn at the same scale to help visualize the differences in stabilities among CA isoforms.
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CA XIV
The structural characterization of mammalian CA XIV was
started by the crystal structures of the extracellular catalytic
domain of murine CA XIV (Whittington et al., 2004). The S–S
bond characteristic for other membrane-bound CA (Cys23–
Cys203) is found in the murine enzyme. The N-glycosylation is
detected at the residue Asn195. Murine CA XIV in the crystal
structure is monomeric. In the structure of the CA XIV complex
with 2, H-bonds are detected between 2 and Thr199-200. The
human CA XIV was first characterized by the crystal structure
of its extracellular domain in complex with 2 (Alterio et al.,
2013). The H-bonds of 2 with water are found besides H-bonds
to Thr199–200.
Summary of the X-ray crystallographic structures of
unliganded human CA isoforms
The X-ray crystallographic structures of the 10 out of 12 catalyt-
ically active human CA isoforms that are available in the PDB are
shown in the Supplementary Fig. 1. There are no structures of CA
VA and CA VB available in the PDB. Seven of the 10 structures
are monomers, while CA VI, CA IX, and CA XII are dimers.
Studies of CA stability and mimicking the active site of another
isoform
Improving the stability of CA II
CAs are some of the most efficient enzymes that make them a
good choice for industrial applications. One of the proposed
applications could be a large-scale fixation of greenhouse gases.
Reaction conditions used in modern technology are rather rigor-
ous, so it makes sense to try to improve the performance of CAs
by mutations using all the wealth of the structural information
available. A lot of crystallographic studies were performed in
order to improve the thermostability (Fisher et al., 2012b;
Boone et al., 2013b, 2015) of human CAs, by introducing muta-
tions as proposed by thermostable CA structures (Fiore et al.,
2013; Diaz-Torres et al., 2015; Simone et al., 2015).
The role of cis-Pro202 in CA II was accessed by mutation to
alanine (Tweedy et al., 1993), the catalytic activity of the mutant
remained unchanged, but its stability was reduced. Interesting to
note, that the cis-peptidyl conformation remained in the crystal
structure of the mutant. Mutational analysis of the aromatic res-
idues clustered around Phe226 (Boone et al., 2013a) revealed its
importance for the stability of the protein, with no effect on the
activity.
There were also studies (Monnard et al., 2013; Heinisch et al.,
2015) aimed to create an artificial transfer hydrogenase.
Mimicking of the active site of CA IX in CA II
The high similarity of α-class CAs and the difficulties with the
crystallization of recombinant CA IX prior to 2015 prompted
the construction of CA II point mutants-chimeras that were
intended to mimic the CA IX active site. All these studies were
used in the search of CA IX-specific inhibitors that have low affin-
ity to CA I and CA II.
The crystallographic study of chimeric CA IX was started by
McKenna group with two mutations: S65A, Q67N (Genis et al.,
2009; Sippel et al., 2011; Tars et al., 2013). In the next version
of CA IX chimera, 8 mutations was introduced: A9K, S65A,
Q67N, T69E, L91I, V131F, E170K, A204L (Pinard et al., 2013).
Chimeric CA IX containing 6 mutations (S65A, Q67N, L91I,
V130F, L134V, A203L) was also designed by our group and its
interaction with the fluorinated benzenesulfonamides was com-
pared with other human CAs (Dudutienė et al., 2014). Slightly
different set of seven mutations (S65A, Q67N, T69E, L91I,
V130F, E169K, A203L) was also designed (Moeker et al., 2014a;
Mahon et al., 2015a; Pinard et al., 2015) and an additional muta-
tion (Q214E) was added to this set (Mahon et al., 2015b).
The crystal structures of CA IX purified by Tars group from
yeast (Leitans et al., 2015) which could be easily co-crystallized
with ligands of interest seem to make this direction in human
CA research less important.
Mimicking of the active site of CA XII in CA II
Our group also reported the crystal structure of CA II mimicking
CA XII (chimeric CA XII) with mutations S65A, K67N, T91I,
A130F, S134V, N203L (Dudutienė et al., 2014). The purpose of
this construct was to illustrate the suitability and relevance of
the chimeric CAs for inhibition studies. The chimeric CA XII
both structurally and thermodynamically bound ligands like a
real CA XII in a manner that significantly differed from CA II
thus proving the approach to be highly suitable for the testing
of compound selectivity.
X-Ray crystallographic studies of human CA complexes with
inhibitors
The main purpose of crystallographic studies is to design isoform-
selective compounds that could be used for the treatment of var-
ious human disorders in which CAs are involved.
Sulfonamides
The relatively small compound trifluoromethane sulfonamide
(TFS) binds to CAs very effectively due to its low pKa (5.9–6.2)
and its complex with CA II was crystallized (Haakansson and
Liljas, 1994). The position of the ligand was compared with the
crystal structure of CA II-2 complex (Vidgren et al., 1990). It is
interesting that the oxygen atoms of sulfonamide in
CF3SO2NH2 were directed opposite to oxygen atoms in 2. CF3
fits into the hydrophobic cleft, whereas the aromatic inhibitor
must be oriented outwards. Another small molecule,
N-hydroxysulfonamide, is bound in the crystal structure of CA
II (Temperini et al., 2007c).
Benzene non-primary sulfonamides
Two crystal structures of benzenesulfonamide with OH or
methoxy substitution at N of sulfonamide in CA II are presented
by Fiore et al. (2011).
para-Benzenesulfonamides
Bio-sensors and fluorescent labels. The binding of benzenesulfo-
namide with various attached fluorophores and other compounds
was tested with CA II as a component of various bio-sensors.
In the crystal structure of fluorophore dansylamide
(5-dimethylamino-1-naphthalene sulfonamide) when bound to
CA II, the unusual orientation of the naphtyl ring towards the
hydrophobic pocket of the active site requires conformational
shift of Leu198 (Nair et al., 1996). The use of fluorescent sulfona-
mide compounds in CA II-based zinc bio-sensors is discussed.
In addition to dansylamide fluorophore (Nair et al., 1996),
fluorescein-derivatized arylsulfonamide was tested as a part of
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zinc bio-sensor based on benzenesulfonamide–CA II interaction
(Elbaum et al., 1996). The fluorescein-containing compound
and its precursor bound to CA II via benzenesulfonamide, but
the fluorescein moiety was not resolved in the crystal. The similar
compound was used for the development of hypoxic tumor imag-
ing system, but the linker connecting the benzenesulfonamide and
fluorescein moieties was shorter (Alterio et al., 2006). Fluorescein
is clearly visible in the structure and exposed out of the active site
cavity and interacts with the helix 130–135.
The high affinity of benzenesulfonamides for CA II was used
in an unusual way for the structural visualization of the
Xe-caging agent cryptophane (Aaron et al., 2008). The crypto-
phane with caged Xe atom was fairly visible in the CA II crystal
pressured with Xe.
CA II binding with benzenesulfonamides was also used in the
development of specific protein detection strategy using TFG
(two-faced guest) approach. TFG is a bifunctional compound
that binds cucurbit[6]uril. When TFG is captured by the enzyme,
unreacted cucurbit[6]uril binds Xe in solution for quantification
by NMR (Wang et al., 2016). The binding of three TFG candidate
compounds to CA II was compared. All of them were bound in
the active site hydrophobically.
Model systems. CA II is also used as a model system for purely
biophysical research: a crystallographer has a good chance to
see in the crystal structure various small molecules as well as sul-
fonamides with various substituents.
Benzenesulfonamides with aliphatic and fluorinated hydrocar-
bon tails were used in the study of the hydrophobic effect
(Mecinović et al., 2011). It was found that fluorocarbons are indis-
tinguishable from hydrocarbons when bound to CA II, and all the
differences in binding affinities are explained by hydrophobic sur-
face changing between ligands. Similar research was performed
with tricycled sulfonamides (Snyder et al., 2011; Lockett et al.,
2013).
Another direction of the research was the use of CA II as a tool
for investigation of Hoffmeister series ions (Fox et al., 2015). Four
structures presented in this study were analyzed with respect to
water network changes upon the binding of anions and interac-
tion of anions with the protein surface. Anions are known to be
weak inhibitors of CAs. Br−, I−, SCN−, and ClO−4 have different
hydration abilities. For example, I− and Br− were found associated
with hydrophobic parts of the active site cavity and significantly
changed the water network.
The effect of fluorination on the interaction with CA II Phe131
was also investigated in detail using crystal structures of CA II
with series of N-(4-Sulfamylbenzoyl)-benzylamines (Kim et al.,
2000, 2001). N-(4-Sulfamylbenzoyl)-benzylamines were produced
systematically introducing fluorine atoms into the second benzene
ring that in the WT enzyme forms edge-to-face interaction with
Phe131. Crystal structures of WT CA II were compared with
structures of the F131V mutant with the same inhibitors. So the
CA II-benzenesulfonamide ligand system was used successfully
to study weak interactions. Comparing binding of ligands with
varied degree of fluorination, the authors observed the different
variants of aromatic interactions in mutant CA II.
CA II interaction with benzenesulfonamide was used in order
to verify the computational approach for drug design
(Combinatorial small molecule growth algorithm) (Grzybowski
et al., 2002). Two molecules were predicted to bind to CA II in
a different way and structures presented in the study confirmed
the predictions.
A tethered azide/alkyl cycloaddition reaction was performed
using target-guided synthesis in the active site of CA II mutant
H64C (Wischeler et al., 2011). CA II was used as a model system
in the click chemistry. Azide component was attached to the
Cys64 by a disulfide bond and alkyl was coordinated at zinc via
benzenesulfonamide. Crystal structures of reactants and product
in CA II are presented. The reaction was stereo-selective and no
Cu(I) was added.
Recognition of protein surfaces by synthetic foldamers was
studied using CA II (Buratto et al., 2014). Foldamers were func-
tionalized by benzenesulfonamide in order to keep at the protein
surface. Interestingly, foldamers bound to two protein chains
dimerized through the stacking interactions of two helices.
Foldamers are additionally fixed at the surface of the protein by
coordination of zinc located at the secondary Zn-binding site
The crystal structure of CA II–benzenesulfonamide with a
bulky thiophene-containing tail was described as a part of the
purely crystallographic analysis of high-resolution structures of
CA II (Behnke et al., 2010). The crystal structure was compared
with 13 high-resolution structures of CA II and refined to the res-
olution of 0.9 Å. Benzenesulfonamide moiety has a good electron
density, whereas the tail is rather flexible, as seen from the poor
density and highly anisotropic B-factors. The paper discusses
the variable parts of the protein by comparison of 14 high-
resolution structures. The inhibitor was chosen just to fill up
most of the active site.
Inhibitors of CA II. A series of homologous benzenesulfonamides
having ethylene glycol tail with attached amino acids in para-
position of the benzene ring was investigated as CA II inhibitors
(Boriack et al., 1995). Ethylene glycol tails were bound in the
active site hydrophobically, amino acids were protruded from
the active site cavity and were disordered in the crystals.
A new class of ‘two-prong’ inhibitors of CAs was proposed,
which carry the cupric iminodiacetate that can bind
solvent-exposed histidines besides benzenesulfonamide moiety
that binds to ZnII (Jude et al., 2006). Structures demonstrated
the binding of the inhibitors to His64 in CA II and His200 in
CA I. All compounds were bound also at the secondary binding
site near the N-terminus of the protein.
Inhibitor based on benzenesulfonamide with glycosyl moiety
was tested as a promising antiglaucoma agent (Fiore et al.,
2007). The compound bound to CA II with the glycosyl moiety
oriented towards a hydrophilic part of the active site cavity.
This study paralleled the research, where sugars were directly
derivatized by sulfonamide (Lopez et al., 2009), and mono-
saccharides containing sulfamate as a zinc-binding group
(Lopez et al., 2011; Moeker et al., 2014a; Mahon et al., 2015b,
2015c). Crystal structures of 4-substituted-ureidobenzenesulfona-
mides demonstrated variable hydrophobic interaction in the
active site (Pacchiano et al., 2010).
Ferrocene and ruthenocenes were co-crystallized with CA II as
benzenesulfonamide derivatives (Salmon et al., 2012). The idea
was to occupy more fully the hydrophobic part of the active site
using bulky hydrophobic organometallics. Complexes fit well,
the hydrophilic part is occupied with glycerol or solvent. Yet
another exotic CA II inhibitor is the hexamethylcyclohexane at
ruthenium in the piano stool-Ru complex (Monnard et al.,
2011). The complex makes π-aromatic interaction with Phe131.
Yet another crystal structure of the different piano-stool complex
with rhenium was also presented with the view of inhibition of
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cancer-relevant CAs and its technetium analog could be useful in
tumor imaging (Can et al., 2012).
4-Sulfamoylphenyl-ω-aminoalkyl ethers with varied linkers
were tested as antiglaucoma agents. Structures of one of them
and its Boc-protected variant were solved when bound in CA II
(Bozdag et al., 2014b), both ligands bound in the same way,
between Phe131 and Pro202. In crystal structures of benzenesul-
fonamide containing lipophilic 4-alkoxy- and 4-aryloxy moieties,
the compounds coincide perfectly in the active site and are bound
hydrophobically (Carta et al., 2015). The pain modulating activity
of one of the ligands was demonstrated in vivo. The crystal struc-
ture of photochromic azobenzene benzenesulfonamide with vari-
ous electron-donating or withdrawing groups (Runtsch et al.,
2015) have demonstrated that azo-group is not perfectly planar
and second benzene ring is located between Pro202 and Phe131.
Inhibitors discriminating CA I and CA II. A significant problem
of selectivity between the active sites of CA I and CA II was
approached with a series of simple benzenesulfonamide contain-
ing para-substituents of a variable charge (Srivastava et al., 2007).
Positive charges are less tolerated in CA I, whereas negatively
charged compounds bind equally well in both isoforms. Three
crystal structures of CA I with compounds of interest were
provided.
Anticonvulsant 4-aminobenzenesulfonamides with branched-
alkylamide moieties were tested as inhibitors of CA I, CA II,
CA VII, and CA XIV, expressed in the brain. Three compounds
were co-crystallyzed in CA II and showed a similar binding
mode, mostly by hydrophobic interactions (Hen et al., 2011).
Seven crystal structures of 4-[N-(substituted-4-pyrimidinyl)-
amino]-benzene-sulfonamides were presented in a crystallo-
graphic and binding thermodynamic study of several human
CA isoforms (CA I, CA II, CA VII, and CA XIII) (Sūdžius
et al., 2010). Electron-withdrawing groups were introduced in
order to enhance the interaction of ligands with the hydrophilic
part of the active site and the linker length was varied.
The ligand combining two Zn-binding groups was developed
as the possible isoform-selective inhibitor (D’Ambrosio et al.,
2012). In the presented crystal structure benzenesulfonamide is
bound to zinc via sulfonamide, whereas sulfamide moiety made
H-bonds with water in the active site. Interestingly, a secondary
molecule of the ligand was found at the entrance of the active
site in the crystal structure.
A series of N-aryl-β-alanine derivatives and diazobenzenesul-
fonamides were synthesized and their binding affinities towards
several CAs were investigated (Rutkauskas et al., 2014). In the
crystal structures of two compounds, the first benzene ring is
positioned in the same way, second rings are bound similarly
between Pro202 and Phe131.
Inhibitory activity of 1,1′-biphenylsulfonamides was tested
against CA I, CA II, CA IX, CA XII and CA XIV (La Regina
et al., 2015). These larger compounds were aimed towards inter-
action with residues 127–136 which differ in CA II and CA XIV.
Compound with the highest Ki for CA XIV was crystallized in CA
II and CA XIV. First rings of the compounds were positioned
similarly in both isoforms, second rings differed, whereas the
third rings were resolved poorly. H-bond is found between
Ser132 in CA XIV and the carbonyl group of the linker.
Isoform-selective inhibitors of CA IX. Many binding, inhibition
and structural studies of human CAs were devoted to the design
of inhibitors of CA IX and CA XII, the targets against certain
types of cancer (Pastorekova et al., 2008). Such inhibitors should
be isoform-specific in order not to interfere with the ubiquitous
CA I and CA II.
One of the candidate compounds was benzenesulfonamide
with the positively charged trimethylpyridinium para-substituent.
The compound was tested for anti-tumor activity and crystallized
in CA II (Menchise et al., 2005). The charge made the compound
membrane-impermeant. The pyridinium moiety made a
face-to-face stacking with Phe131 and was bound at the hydro-
philic part of the active site.
Another interesting approach for creating CA IX-selective
inhibitors is based on the design of hypoxia-activated inhibitors
containing mercapto-group. Benzenesulfonamide containing
3,3′-dithiodipropionamide- or 2,2′-dithiodibenzamido- moieties
were tested and one of the compounds was crystallized in the
reduced (thiolic) form with CA II (De Simone et al., 2006).
Two selective arylsulfonamide inhibitors of CA VII, CA IX,
and CA XIV were crystallized bound to CA II (Gitto et al.,
2012). The second rings of both compounds have alternate posi-
tions in the active site. Heteroaryl-benzenesulfonamides were
tested as isoform-specific inhibitors with several CA isoforms
and their binding to CA II was analyzed in five crystal structures
(Buemi et al., 2015). Ligands in all five structures coincided well
and were bound hydrophobically.
The adamantyl-containing benzenesulfonamide (Biswas et al.,
2013a) was compared as an isoform-selective compound with its
thiadiazole-counterpart (Avvaru et al., 2010c). The replacement of
the tricyclic ring with benzene improved the inhibition profile.
On the other hand, the first ring of ligands in superimposed struc-
tures occupies the same position, but the adamantyl groups are
positioned on different sides of the Phe131.
Another example of aryl-benzenesulfonamide (Güzel-Akdemir
et al., 2013) ligand was compared with several other aryl-
benzenesulfonamides (De Simone et al., 2006; Pacchiano et al.,
2010; Carta et al., 2011; Hen et al., 2011). Inhibitor bound at
the hydrophobic part of the active site between the side chains
of Phe131 and Pro202.
Coumarinyl-substituted benzenesulfonamides were tested
against several human CA isoforms (Wagner et al., 2010). The
crystal structure of one ligand in CA II was described.
Coumarinyl group attached to benzenesulfonamide interacted
with the active site like any other benzenesulfonamide in contrast
to coumarins lacking the sulfonamide group. The stacking inter-
action was found between coumarine ring and phenyl group of
Phe131.
1,3,5-Triazinyl-substituted benzenesulfonamides discussed as
potential inhibitors of human CA and β-class bacterial CAs
(Carta et al., 2011) were crystallized in CA II. Triazine ring was
found stacked with the side chain of Phe131. Two compounds
were located in the CA II active site in a very similar way.
The crystal structure of an anticancer drug E7070, which is a
para-substituted benzenesulfonamide was reported, but not
found in the PDB database (Abbate et al., 2004a).
para-meta-Benzenesulfonamides
Inhibitors of CA II. One of the earliest crystallographic studies of
inhibitors bound to CA II was the 4-aminobenzenesulfonamide
with mercury at the 3rd position of the benzene ring (Eriksson
et al., 1988b).
Two human CA inhibitors that differ only by the fluorine at
meta-position of the benzene ring showed different conforma-
tions of the second ring in the complex with CA II (Biswas
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et al., 2011). The interaction of inhibitors with CA II was designed
by a new strategy of ‘virtual screening’ as an alternative to the
high-throughput screening (Grüneberg et al., 2002). The method
was based on the analysis and docking of known structures. Two
predicted compounds were analyzed structurally.
Isoform-selective inhibitors. 1-N-Alkylated-6-sulfamoyl saccharin
derivative that was unintentionally hydrolyzed during X-ray
experiment was further developed into the inhibitor showing
selectivity between CA isoforms (Ivanova et al., 2015).
Benzenesulfonamides containing TEMPO (2,2,6,6-tetrame-
thylpiperidine-1-oxyl) moiety in the para- or meta-positions
and Cl in the meta-position showed inhibition of human CAs
(Ciani et al., 2009). Such compounds could be used for spin-
labeling studies. ESR (electron spin resonance) spectra differed
between isoforms. The TEMPO moiety was slightly disordered
in the crystal structure.
The crystal structure of sulpiride, an anti-psychotic drug,
bound to CA II is reported, but not found in the PDB database
(Abbate et al., 2004b).
ortho-Benzenesulfonamides
The binding of halogenated benzenesulfonamide was character-
ized thermodynamically and crystallographically (Scott et al.,
2009). Both 2-substituted benzenesulfonamides showed very dif-
ferent binding profiles and positions in the active site of CA II.
Whereas the position of benzenesulfonamide ring was the same
in both structures, the orientation of the thiophene tails differed.
Fluorinated para-benzenesulfonamides
A detailed binding and crystallographic study of fluorinated para-
substituted benzenesulfonamides were supplemented by three
crystal structures of the compounds bound to CA II, CA XII,
and CA XIII (Dudutienė et al., 2013). Fluorination of the benzene
ring especially enhanced the binding to CA I. Two possible orien-
tations of benzene ring were revealed in the crystal structures of
CA XII and CA XIII with ligands.
The studies of fluorinated para-substituted benzenesulfona-
mides were continued further (Zubrienė et al., 2015). These com-
pounds showed exceptionally strong binding to CA I because the
fluorination increased the fraction of deprotonated ligand. Three
crystal structures of CA I and the structures of CA II and CA XII
in complex with four ligands were described and compared with
related compounds (Dudutienė et al., 2013). The study revealed
variation in the positions of the first ring of inhibitors in CA II
and CA I.
Fluorinated para-meta-benzenesulfonamides
Structural and thermodynamic investigations of fluorinated ben-
zenesulfonamides were continued with crystal structures of
three compounds containing substituents in meta- and para-
positions bound in CA II, CA XII, and CA XIII (Dudutienė
et al., 2015). In CA XIII, fluorinated benzene ring was found
only in a single position, whereas in CA II and CA XII the posi-
tion of the benzene ring could vary.
Chlorinated meta-benzenesulfonamides
Compound 5-nitro-2-Cl-benzenesulfonamide as a precursor of
the series of ligands could be reduced, thus aiming towards the
hypoxia-inducible CA IX (D’Ambrosio et al., 2008a). The crystal
structure supplemented the inhibition studies.
A face-to-face stacking interaction with Phe131 was found in
the crystal structure of sulfonamide-based diuretic drug indapa-
mide (Temperini et al., 2008b). The comparison with the crystal
structure of other diuretic drug chlorthalidone bound to CA II
(Temperini et al., 2009) showed the different binding mode of
the drug in its enol form, making H-bonds with waters ordered
in the active site and the side chain of Asn67.
The series of indapamide-like N-alkylated benzimidazoles was
compared with S-alkylated benzimidazole derivatives thermody-
namically and structurally in crystal structures with CA II
(Čapkauskaitė et al., 2010). The position of the Cl-benzene ring
in all crystal structures was determined by Cl atom bound to
the hydrophobic pocket of the active site, and tails were directed
in the same way as indapamide itself making H-bonds with the
residue Asn62 by linker atoms. Analysis of the thermodynamic
parameters of binding showed that S-alkylated compounds were
more effective CA inhibitors, probably due to better H-bond pat-
tern and larger hydrophobic area.
Chlorinated para-meta-benzenesulfonamides
Four crystal structures of para-meta-substituted chlorinated ben-
zenesulfonamides were presented in the comprehensive research
trying to connect the intrinsic thermodynamic parameters of
ligand binding to several CA isoforms with the structural infor-
mation (Kišonaitė et al., 2014). The influence of chlorine in ortho-
position and positions of the four different tails on the thermody-
namic parameters of binding was analyzed.
The binding of two series of inhibitors, namely,
[(2-pyrimidinyl-thio)-acetyl]benzenesulfonamides, that con-
tained Cl at the position 2 of the benzene ring and tail at the
meta-position and Cl-free ligands substituted at para-position
of the benzene ring, were compared thermodynamically and
structurally (Čapkauskaitė et al., 2012). Chlorine atom deter-
mined the positioning of the first ring and analysis of the binding
thermodynamic parameters showed better selectivity of the first
group of compounds towards CA I, CA II, CA VII, and CA
XIII. Cl-free ligands showed better binding but lower selectivity.
These studies were continued further (Čapkauskaitė et al.,
2013). Two series of ligands described already (Čapkauskaitė
et al., 2012) were complemented with meta-benzenesulfonamide
without Cl and para-benzenesulfonamide with Cl. Crystal struc-
tures of three compounds with CA II, CA XII, and CA XIII
were described in this work. In common, the binding affinities
of para-substituted compounds were higher. One of the com-
pounds was the selective nanomolar inhibitor of CA I.
di-Benzenesulfonamides
Crystal structures of three benzene-1,3-disulfonamide derivatives
bound in CA II demonstrated that the sulfonamide group in
meta-position is directed towards the hydrophilic part of the
active site and made H-bonds with residues His64, Asn67,
Gln92, and Thr200 (Alterio et al., 2007). The benzene ring was
found in the position, that was relatively rare in known structures
of benzenesulfonamide inhibitors bound to CA II.
Heterocycles
Thiophenes and thiazines
Three crystal structures of thiophenesulfonamides with substitu-
ents of varied length at the 4-amino group were analyzed
(Smith et al., 1994). One of these compounds was the dorzola-
mide drug. The only difference in the binding of these ligands
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in CA II was the displacement by the dorzolamide of the proton
shuttle residue of CA II–His64.
Inhibitors based on the structure of the topical antiglaucoma
drug brinzolamide were compared as inhibitors of CA II and
CA IV (Kim et al., 2002). These compounds are nanomolar inhib-
itors of CA II. Morpholino group and the hydrophobic tail were
located at the residue Val135. Positions of the heterocyclic ring
depended on the second substituent.
The binding of bicyclic thienothiazene-6-sulfonamide-1,1-
dioxide nanomolar inhibitors to CA II was structurally compared
with monocyclic 2,5-thiophenedisulfonamides (Boriack-Sjodin
et al., 1998). The second sulfonamide group served for the intro-
duction of substituents that interact mostly with the hydrophobic
pocket of CA II active site. These structures helped to understand
the mechanism of action of the perspective antiglaucoma drug
brinzolamide (Stams et al., 1998).
The crystal structure of CA II with another variation of the
dorzolamide scaffold was presented (Steele et al., 2009), where
the nitric oxide donating moiety is combined with the drug
with the aim to develop a dual action antiglaucoma drug.
The crystal structure of thiophenesulfonamide with naphtalene
substituted triazole ring represents a group of inhibitors, that were
synthesized by click-chemistry (Leitans et al., 2013). These com-
pounds were micromolar inhibitors of CA I and nanomolar – of
CA II. Bulky substituents at triazole were proposed to mediate the
selectivity towards CA II. Their tails were differently located in
crystals.
Thiazoles and thiadiazoles
The use of thiadiazole-based ligands in human CA inhibition
studies represented a further development of acetazolamide
drug that is in a clinical use for decades.
The linker between sulfonamide group and thiadiazole ring
can influence the binding mode of the inhibitor in CA II as
was demonstrated in several studies (Fisher et al., 2006;
Temperini et al., 2008a). Two crystal structures of CA II com-
plexed with thiadiazolesulfonamide with halogenated benzene
tail were compared (Menchise et al., 2006). One of them was
found in the structure lacking any substituent, probably due to
the hydrolysis. The crystal structure of thiadiazolesulfonamide
with a very long tail of nitrooxybutylbenzoate in CA II
(Mincione et al., 2011) illustrated the inhibition studies of a series
of nitric oxide-donating CA inhibitors that could be antiglaucoma
drugs. This study paralleled a research of imidazolesulfamides
containing the nitro group (Rami et al., 2013).
Sugars
Mono- and disaccharides derivatized by sulfonamide were studied
as putative isoform-selective CA inhibitors and their binding to
CA II was compared with the sulfamate Zn-binding group con-
taining drug topiramate (Lopez et al., 2009). The hydrophilic
sugar moiety has low membrane permeability. Therefore, it is
thought to provide in vivo selectivity towards transmembrane
CA IX and CA XII.
Other heterocycles
A crystal structure of a tricyclic sulfonamide (benzimidazo[1,2-c]
[1,2,3]thiadiazole-7-sulfonamide) bound to CA II was described
(Baranauskienė et al., 2010). This relatively rigid compound is
fixed by van der Waals interactions within the active site.
A crystallographic analysis of a series of homologous heterocy-
clic compounds with sulfonamide group bound in CA II was used
in the studies of the hydrophobic effect (Snyder et al., 2011).
Crystal structures illustrated regular changes in the binding ther-
modynamic parameters of homologous ligands. Heterocyclic sul-
fonamides based on furan, imidazole, thiazole, and thiophene
were also extended with the benzene ring in order to increase
the hydrophobic surface. The conclusion was that the distortion
of structured water was the main driving force of binding. This
study was continued with a series of fluorinated heterocyclic com-
pounds (Lockett et al., 2013), and the crystal structure of CA II
with fluorinated benzothiazole was described and compared
with the previous study. No influence of fluorination on binding
was detected.
Indanesulfonamide-based series of human CA inhibitors was
analyzed (D’Ambrosio et al., 2008b) with two crystal structures
of CA II. Indane rings oriented differently in these structures
due to the different substituents. In the crystal structure of CA
II with indolesulfonamide-based ligand, a nanomolar inhibitor
of CA I and CA II (Güzel et al., 2008), the indole ring was accom-
modated at the hydrophilic side of the active site and made
H-bonds with Asn62 and Asn67 side chains as well as with
water molecules.
In the crystal structure illustrating an inhibition study of a
series of 1-(cyclo)alkylisoquinolinesulfonamides against human
CA isoforms (Gitto et al., 2010), isoquinoline ring was fixed in
the active site by van der Waals interactions. In the crystal struc-
ture of a related compound that differs from the previous study
only by the methyl group (Mader et al., 2011), the ring was
located in a different way. The observation that very small struc-
tural differences could result in relatively large variations of inhib-
itory profiles was further illustrated by a comparison of two
compounds: pyridinesulfonamide and benzenesulfonamide
(Bozdag et al., 2014a). Compounds have the same tails but were
bound very differently in the active site of CA II, and pyridinyl-
sulfonamide had a steric clash with hydroxyl group of Thr200.
Sulfamides
One of the simplest inhibitors structurally characterized was
N-hydroxysulfamide (Temperini et al., 2007c), that is the more
effective inhibitor of CA I and CA II than sulfamide. The com-
pound is bound to zinc like all other sulfonamides by the nitrogen
atom, but not by the hydroxyl group.
Sulfamides comprise yet another variant of the Zn-binding
group and are widely represented in CA crystallography. The posi-
tioning of these ligands has an additional degree of flexibility with
respect to benzenesulfonamides (or other heterocyclesulfonamides,
because of the additional rotation around the nitrogen atom).
The borolane-containing benzenesulfamide was co-crystallized
with CA II due to its possible use in boron neutron capture in the
anticancer therapy (Fiore et al., 2010b). Carboranes bound
through a flexible linker to the sulfamide (Brynda et al., 2013)
also can be effectively bound by CAs and therefore, considered
to have pharmaceutical perspectives. The length of linkers was
chosen in order to fill the active site by the icosahedral carborane
in an optimal way. Crystal structures confirmed the predicted
binding position of ligands by van der Waals interactions with
the protein side chains. This study was continued further
(Mader et al., 2014). Here, high-resolution structure of carborane-
sulfamide bound in CA II was described and used for the model-
ing of the interaction with CA IX.
A series of nitroimidazole derivatives with sulfamide, sulfona-
mide, and sulfamate groups for anchoring to CA were discussed
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in numerous studies. Crystal structure with one of nitroimidazo-
lesulfamides confirmed the inhibition studies (Rami et al., 2013).
These compounds were chosen as possible chemo- or radiosensi-
tizing agents in an anticancer therapy. The electron density was
good and H-bonds of the nitro group with Thr200 and His64
were found.
The other research (De Simone et al., 2014) described inhibi-
tory properties of other series of compounds: phenylmethylsulfa-
mide with substituents optimized to make interactions in the
active site. But-2-yn-1-yloxy tail was found to provide strong
interactions with CA II active site.
Sulfamates
Sulfamates like sulfamides are derivatives of the sulfamic acid
where the substituent is bound via one of three oxygen atoms
at sulfur atom. Most of the sulfamate inhibitors studied are per-
spective anticancer steroid or non-steroid drugs or their
homologs.
Many non-steroid drugs initially designed for other targets
possess sulfamate Zn-binding group. One of the examples is the
anti-convulsant drug RWJ- 37 497, an analog of topiramate crys-
tallized bound to CA II (Recacha et al., 2002). The interaction of
topiramate that belongs to this group of compounds with CA II is
also described (Lopez et al., 2009) as well as its sulfamide analog
(Winum et al., 2006). The crystal structure of 667-coumate, a
potent non-steroidal inhibitor of steroid sulfatase (anticancer
drug) based on a coumarine ring bound to CA II was reported
and the mechanism of the drug stability in vivo due to its seques-
tration by CA II in blood was proposed. The tricyclic coumarine
was proposed to mimic steroid structure. The electron density of
the 7-membered ring was not very good due to flexibility (Lloyd
et al., 2005a). In the structures of CA II with aromatase-steroid
sulfatase inhibitor analogs possessing sulfamate Zn-binding
group (Lloyd et al., 2005b), the sulfamate-containing rings in
both cases nearly coincided, but the para-substituents differ in
binding to the protein. Steroid sulfatase inhibitors were seques-
tered in blood by binding to CA II via sulfamate moiety. This
interaction is favorable from the pharmacokinetics point of view
and several structures of CA II complexes with similar ligands
were reported (Leese et al., 2006; Woo et al., 2008, 2010; Cozier
et al., 2010).
Microtubule disruptor crystal structure in complex with CA II
(Leese et al., 2008, 2010) was yet another example of the antican-
cer drug which bioavailability was increased by interaction with
CA. Antiproliferative bis-sulfamates and steroid sulfatase
inhibitor-CA II structure (Leese et al., 2006) revealed the binding
of two molecules in the active site. One molecule was coordinated
at zinc by sulfamate in an unusual way, the other filled the rest of
the cavity. The binding of estradiol-sulfamate compounds in CA
II and its double mutant, mimic of CA IX, were compared (Sippel
et al., 2011). These compounds could have an antiproliferative
effect, and the aim of the study was to find a CA IX-specific inhib-
itor that binds stronger to CA IX, but still could be sequestered by
CA II.
Rather an unusual set of aliphatic mono- and bis-sulfamates
were studied in the search of isoform-specific inhibitors (Vitale
et al., 2009). Four compounds were bound in a similar way in
CA II. The second sulfamate was exposed out of the cavity and
was mobile as could be judged from the increased B-factors.
Monosaccharides with one of the hydrophilic groups deriva-
tized to sulfamate described as inhibitors of human CAs (Lopez
et al., 2011) were also subject to CA II esterase activity. The
loss of acyl groups was observed as well as an inversion of stereo-
chemistry. Carbohydrates carrying sulfamate as a Zn-binding
group containing various linkers were studied with the goal of
designing CA IX-specific compounds (Moeker et al., 2014a).
Binding of two compounds with CA II and CA IX mimic
(Pinard et al., 2015) was studied crystallographically.
Carbohydrate moiety as a tail group was chosen due to its
lower membrane permeability. The topic hydrocarbonate-based
sulfamates as isoform-selective human CA inhibitors were devel-
oped further (Mahon et al., 2015b, 2015c). Together with the
analysis of the ligand binding in CA II and CA IX mimic, the arti-
fact of acetylation of the surface lysine and its effect on the protein
stability was discussed (Mahon et al., 2015c).
Abbate et al. (2004c) reported the crystal structure of antiendo-
crine drug showing both CA and estrone sulfatase inhibition
activity: EMATE-sulfamate complex with CA II.
Natural products: alternative metal-binding groups and
products of hydrolysis
Small organic Zn-binding groups
Small organic compounds often bind to zinc in a position similar
to bicarbonate substrate. One of the examples is acetate. Acetate
mimics the binding of substrate (Haakansson et al., 1994a), but
the latter different position of acetate in the CA active site was
also found (Mazumdar et al., 2008). Azide and bromide have
an affinity to zinc and were also co-crystallized with CA II
(Jonsson et al., 1993). Sulfide and nitrate in CA II were bound
at zinc forming a trigonal bipyramide coordination sphere
(Mangani and Hakansson, 1992). In the complex of CA II with
SCN− at pH 8.5 (Eriksson et al., 1988b) sulfur displaced the
deep water. Zn-bound water remained in this structure and zinc
was pentacoordinated (Eriksson et al., 1988b). Bisulfite and for-
mate complexes in CA II were crystallized at neutral pH
(Haakansson et al., 1992). Bisulfite was bound to zinc by an oxy-
gen atom, replacing the Zn-bound water. Formate, lacking a
hydroxyl group, bound in a similar position and made H-bond
with the main chain nitrogen of Thr199 between the zinc ion
and the hydrophobic part of the active site.
Cyanate was reported to bind in a CO2 binding site, where
Zn-bound water kept the position as a metal ligand (Lindahl,
et al., 1993). Different ways of cyanate binding were found in
the structures of WT CA II and V207I mutant with cyanate
(West et al., 2014). The anion was bound directly to Zn finishing
a tetrahedral coordination sphere.
The positioning of CS2−3 Zn-binding group was investigated by
solving the structure of CA II with trithiocarbonate (Temperini
et al., 2010). The trithiocarbonate was bound in a monodentate
way to zinc and its position was the same as that of bicarbonate
but differed by orientation from urea (Briganti et al., 1999),
which made two H-bonds with the main chain nitrogen of
Thr199 and its hydroxyl group and with two water molecules.
1,2,4-triazole bound in CA II also replaced Zn-bound water,
formed H-bonds with Thr199–200 and filled the proposed posi-
tion of the substrate (Mangani and Liljas, 1993).
Dithiocarbamates investigated as potential inhibitors of human
CAs were bound to zinc in a monodentate way by sulfur atom
and made interactions with active site residues (Carta et al.,
2012a, 2012b).
Crystal structures of several inhibitors based on hydroxyben-
zoic acid and phenol bound to CA II were determined (Martin
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and Cohen, 2012). Phenol and benzoic acid derivatives made a
H-bond with the Zn-bound water. Some of them formed
H-bonds with water molecules and active site residues as well.
Polyamines as a Zn-binding group were also studied (Carta
et al., 2010). Spermine was not coordinated directly to zinc, the
terminal aminogroup formed an H-bond with the Zn-bound
water and Thr199. Other aminogroups also formed H-bonds
with Thr200-Pro201 and had a clash with the side chain of Gln92.
Hydroxamates
Several compounds previously characterized to inhibit other met-
alloenzymes but were found to influence the activity of CA as
well. Example of such ligand was acetohydroxamic and trifluoroa-
cetohydroxamic acid (Scolnick et al., 1997). The monodentate
binding of the compound through its nitrogen atom (deproto-
nated) is similar to bicarbonate. N-Hydroxyurea differs from
the acetohydroxamic acid by CH3 replaced with NH2.
N-Hydroxyurea representing yet another Zn-binding group was
bound to zinc in a bidentate way by nitrogen and oxygen atoms
(Temperini et al., 2006b). Hydroxamates were investigated further
with the crystal structure of benzhydroxamic acid bound in the
active site of CA II (Di Fiore et al., 2012).
Cyanamides were hydrolyzed by CA II (Briganti et al., 1999;
Guerri et al., 2000). After incubation of CA II with cyanamide,
urea was found in the crystal structure. Cyanamide is isoelectronic
with CO2 and subject to hydrolysis by CA II (Briganti et al.,
1999). Ureate was bound to zinc as a monodentate ligand and
made H-bond with hydroxyl of Thr199 and several H-bonds
with water molecules.
Thioxolone: hydrolysis products
The antipsoriatic drug thioxolone was shown to be hydrolyzed by
CA II (Barrese et al., 2008). The resulting compound 4-mercapto-
benzene-1,3-diol or 2-mercaptophenol remained bound to zinc as
a fourth ligand by the thiol group. The intermediate compound
S-(2,4-thiophenyl)hydrogen thiocarbonate was located in the struc-
ture at the entrance to the active site. An interesting case of oxidation
of the thioxolone hydrolysis product by X-ray generated radicals
bound to CA II was published (Sippel et al., 2010). The resulting
compound was bound to zinc via the hydroxyl group.
Other metal-binding groups were explored: 1-hydroxy-2-
sulfanylpyridinium was studied crystallographically with the aim
to find alternative metal-binding groups that would bind zinc in
a bidentate way (Wischeler et al., 2010). Indeed it was found in
the crystal structure of CA II that zinc coordinated sulfur and
hydroxyl. The compound is a part of the H-bond network involv-
ing several water molecules.
A series of compounds based on the similar Zn-binding group,
but having different heterocycle, namely allothiomaltol and thio-
maltol, was also studied (Martin et al., 2014a). Compounds differ
only by the methyl group position. Both ligands were bound
directly to zinc but in a different way. Thiomaltol was bound in
monodentate mode by sulfur and two conformations were mod-
eled, whereas allothiomaltol was in the crystal structure as a biden-
tate ligand. The binding of thiomaltol would be expected to be
similar to 2-mercaptophenol (Barrese et al., 2008). Allothiomaltol
nearly coincided with 1-hydroxy-2-sulfanylpyridinium (Wischeler
et al., 2010). Its methyl group fitted well into the hydrophobic cav-
ity in the active site. It is an interesting study trying to show that
interaction with local protein active site environment may influence
the metal binding with rather significant effects.
A comprehensive crystallographic study of pharmacophores
related to 1-hydroxy-2-sulfanylpyridinium was undertaken by
systematically varying the position of the methyl group in rela-
tively small compounds (Martin et al., 2014b). Small structural
differences between ligands resulted in dramatic changes in the
position of ligands due to the interaction with highly ordered
water network in the active site. The mono- or bidentate binding
was ruled mostly by the local interaction of the substituents with
protein and correlated with the inhibitor efficiency.
Coumarins: products of hydrolysis
An interesting example of the inhibition by hydrolysis product
was described in an attempt to get crystal structure of coumarin
derivative with CA II (Maresca et al., 2009, 2010). The product
of hydrolysis, a derivative of cis-2-hydroxycinnamic acid was
found in the structure. Surprisingly, no interaction with zinc
was found, but the compound blocked the entrance to the active
site (Maresca et al., 2009). The structure of CA II with the product
of hydrolysis of unsubstituted coumarin was also discussed
(Maresca et al., 2010). The compound also did not contact with
zinc but formed H-bonds to the side chains of His64, Gln92,
and Asn62.
Phenols
The library of phenol-based natural products was analyzed with
respect to inhibition of β-class CAs from human pathogens and
CA I/CA II (Davis et al., 2011). Phenols were chosen because in
the published crystal structure of CA II phenol was bound to
the Zn-bound water by its hydroxyl group (Nair, et al., 1994).
The similar binding mode was found in the structure of CA II
with one of the compounds from the library. The structure of
benzenesulfonamide-derivative of this compound in CA II was
also solved for comparison.
Saccharines
As saccharines were found to be inhibitors of CAs, it was very nat-
ural to try to crystallize CAs with them (Köhler et al., 2007).
Compounds were bound to zinc with the nitrogen atom and
one of sulfanyl oxygen atoms and made the fifth ligand of zinc,
with a rather distorted geometry. Two structures were presented
with the similar binding of a ligand, and the secondary binding
site of saccharine was found in one of the structures. The perspec-
tives of the saccharine analogs as isoform-selective inhibitors were
further investigated in Moeker et al. (2014b). A relatively long tail
was added to the benzene moiety through triazole. A crystal struc-
ture of this saccharine derivative was presented when bound to
CA II. The tail was completely unresolved in the electron density
probably due to multiple conformations.
Saccharine modified by sulfonamide moiety was found in CA
II bound to zinc by sulfonamide, as all other sulfonamide com-
pounds (Alterio et al., 2015). A crystal structure of saccharine
modified with carboxymethyl as Zn-binding group in CA II
was also published (Langella et al., 2015), thus representing a
new Zn-binding group. Carboxylate was bound to zinc as a
monodentate ligand.
Cholines
Cholic acid is a naturally occurring inhibitor of human CAs in the
gastroenteric tract, therefore it was interesting to determine its
crystal structure in complex with CA II (Boone et al., 2014).
Bidentate binding of cholate carboxyl to zinc displaced the
Zn-bound water and shifted the deep water. Hydroxyl groups
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made a lot of water-mediated H-bonds with the protein side
chains in the active site, but no direct H-bonds were found.
The changes on the ordered water network were discussed.
Sulfonamides as drugs
CA I
Protein interaction of CA I with clinically used drugs was studied
rather intensively. There were not many structures of CA I with
inhibitors as a part of drug design studies, probably due to the rel-
atively low catalytic activity of CA I compared with ubiquitous CA
II, which was a subject of intensive inhibitor search.
Three crystal structures of CA I with commercial drugs were
reported (Chakravarty and Kannan, 1994). The 2, 3 and
benzenesulfonamide-Hg compounds were bound to zinc, but sul-
fonamide group was differently oriented. 3 disrupts the H-bond
network. Antiviral drug foscarnet was crystallized bound to CA
I (Temperini et al., 2007a). The drug is interesting because of
an unusual Zn-binding phosphonate group. Foscarnet had some
activator activity on CA I, whereas it is a weak inhibitor of several
other isoforms as revealed by kinetics measurements (Rusconi
et al., 2004). The drug bound to zinc in the inhibitor-like manner
that contradicted the kinetics data. The crystal structure of CA I
with topiramate (Alterio et al., 2010) showed the rearrangement
of the active site compared with CA II, that means conformations
of side chains of Trp5, His67, and His200 differed between the
native CA I and the complex.
CA II
Nonsteroidal anti-inflammatory drugs, inhibitors of the inducible
cyclooxygenase COX-2 were described as inhibitors of several
human CAs (Weber et al., 2004). A crystal structure of CA II
with celecoxib drug was presented. The affinity for CA II could
be expected, as the drug bears the sulfonamide group.
Trifluoromethyl moiety was bound to the hydrophobic wall of
the active site, methylbenzene made contacts with Asn62,
Glu69, and Gln92. The related drug valdecoxib was also crystal-
lized bound to CA II (Fiore et al., 2006). It bounds in a different
way, making stacking interaction with Phe131.
The high-resolution crystal structure of 2 in CA II was pre-
sented (Sippel et al., 2009). Three 2 molecules were found in
the structure. Acetazolamide is used usually as a reference com-
pound in various inhibitor studies or in order to check the effects
of mutations. In crystal structures of L198 CA II mutants in the
unliganded form and with 2 were compared in order to elucidate
the role of this side chain in substrate binding (Nair and
Christianson, 1993; Nair et al., 1995). One of the mutations,
L198F, was a variant that was present in CA III, and significant
conformational changes of Phe side chain occurred upon binding
of inhibitor. A binding of a modified version of 2, which is more
selective towards CA II was presented (Biswas et al., 2013b).
Further modifications of 2 scaffold producing dual-tail inhibitors
were described (Tanpure et al., 2015), where the hydrophilic
glucosyl-tail and hydrophobic phenyl-tail were found in the cor-
responding parts of the active site. Crystal structure of 1, a com-
pound preceding the dorzolamide and brinzolamide drugs bound
to CA II was also described (Di Fiore et al., 2008).
Interaction of an antiepileptic drug topiramate (4) and its sul-
famate and sulfamide analogs was intensively studied (Recacha
et al., 2002; Winum et al., 2006; Lopez et al., 2009). Another anti-
epileptic drug lacozamide has no traditional Zn-binding groups
and nevertheless, it was an inhibitor of human CAs. The complex
of the drug with CA II was crystallized and showed that the bind-
ing mode is similar to the products of hydrolysis of coumarin
(Temperini et al., 2010). It makes no contacts with zinc. There
was another example of the antimetastatic drug not contacting
zinc in CA II, the Ru (III) complex compound NAMI-A [tetra-
chloro(DMSO)(imidazole)-ruthenate(III)] (Casini et al., 2010).
The complex compound was disrupted in the protein, imidazole
was found at ZnII and RuIII was located far away in the entrance
as well as DMSO.
Antihelmint drug thiabendazole was modified with sulfona-
mide and its activity was checked against human CAs and
Caenorhabditis elegans α-CAH-4b (Crocetti et al., 2009). The
crystal structure of CA II with this compound was presented
and discussed in view of human parasite CA inhibition and prob-
ably with clinical perspectives for some human CA isoforms.
CA IV
The structure of murine CA IV (Stams et al., 1998) and also trun-
cated version was compared with human CA IV (Stams et al.,
1996). Murine CA IV was crystallized in complex with brinzola-
mide and compared with CA II (Stams et al., 1998). The affinity
of binding differed significantly between two proteins, structural
differences were discussed: the position of the drug was very sim-
ilar, but in murine CA IV there were fewer contacts with the
inhibitor than in CA II. There was interaction with Phe131,
H-bond with water in CA IV, and tail of the ligand was disordered
in the murine enzyme. An attempt to optimize the dorzolamide
with respect to the binding to CA IV and solubility was reported
(Vernier et al., 2010). Resulting compounds were
para-meta-substituted pyrimidinesulfonamides.
Activators
Activator molecules bind mostly at the entrance of the active site
and participate in the proton transfer pathway. Activator com-
pounds include amino acids, peptides, and amines that may be
easily protonated.
CA I
The first reported case of an activator molecule in the active site of
CA I was the crystal structure of the complex with histidine
(Temperini et al., 2006a). The activation effect of histidine was
explained by the binding to the imidazole ring of His 200 and
involvement to the water network. The binding differed from
that in CA II-His structure (Temperini et al., 2005).
The antiviral drug foscarnet, a weak inhibitor of human CAs,
acted as an activator of CA I (Temperini et al., 2007a). The com-
pound was coordinated to zinc by phosphonate moiety. The
phosphonate made a weak H-bond with imidazole ring of
His200 in CA I active site. The presence of His200 (corresponds
to Thr200 in CA II) made the CA I active site more narrow com-
pared with other CAs and unusual orientation of foscarnet in CA
I could be the reason for its role as an activator.
CA II
The first crystallographically characterized activator of CA II was
histamine (Briganti et al., 1997). The activator bound at the
entrance of the active site cavity and the imidazole moiety was
connected through water network to the proton shuttle residue
His64. The molecule 1-[2-(1H-imidazol-4-yl)-ethyl]-2,4,6-
trimethylpyridinium resulted from an optimization of histamine
(Dave et al., 2011). Unexpectedly, in the crystal structure with
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CA II, the compound was found with the pyridinyl moiety
directed to zinc and making contacts with Phe131 and Pro202.
Imidazole ring of L-histidine was involved in H-bonds with
His64 (and other amino acids), and water molecules connected
the activator to the Zn-bound water (Temperini et al., 2005).
The binding of the stereoisomer D-histidine also made a
H-bond with His64, but otherwise, contacts were different.
D-histidine in the crystal structure was also connected through
water molecules with the Zn-bound water (Temperini et al.,
2006d).
The D- and L-tryptophans were investigated as activators of
various human CA isoforms (Temperini et al., 2008c). In the crys-
tal structure of D-tryptophan in CA II, the activator was bound in
an unusual way as compared with other structurally characterized
activators. The amino acid was bound at the edge of the active site
and contacted to a symmetry-related protein molecule. The bind-
ing of tryptophans was compared with the crystal structure of CA
II with L-adrenaline (Temperini et al., 2007b).
L- and D-phenylalanine, another pair of stereoisomers whose
binding to CA II could be compared structurally. The position of
both ligands differed. Both made H-bond to the His64 residue by
carboxylate (D-phenylalanine) and by an amino group
(L-phenylalanine) (Temperini et al., 2006c).
Addition of the exogenous donor/acceptor of protons could
rescue the proton transfer in H64A mutant of CA II (Duda
et al., 2001, 2003). In this case, 4-methylimidazole was used as
an activator. The water network that could help understand the
mechanism of rescue was visualized in the crystal structures.
The same small molecule. 4-Methylimidazole was used for the
rescue of another CA II double mutant H64W, W5A (Bhatt
et al., 2007). 4-Methylimidazole made a π-interaction with
Trp64. A regular crystallographic study of catalytic activity rescue
of CA II mutant H64A described the binding of four imidazole
derivatives (Aggarwal et al., 2014). Imidazoles were found in mul-
tiple binding sites.
In search for correlations between the X-ray
crystallographic structures of inhibitor-CA complexes and
the intrinsic thermodynamic parameters of their
interaction
Crystallographic studies of CA inhibitors that was reviewed in the
preceding sections provided the structural modes of various com-
pounds binding in the active site of CA. However, crystallographic
investigations can provide only the structural information and do
not provide the energetic picture of binders. Weakly binding and
weakly inhibiting millimolar compounds that do not have poten-
tial to be developed as drugs would be indistinguishable in the
crystallographic structures from nanomolar or picomolar com-
pounds that have potential to be developed as drugs. In the pro-
cess of crystal growth in the presence of a binding compound or
crystal soaking with an inhibitor, the concentration of the com-
pound used in the experiment usually is in the millimolar
range. The electron density of the bound compounds can be
clearly visible both for weak and tight binders.
Therefore, as discussed above, it is important to use biochem-
ical and biophysical methods together and accurately determine
the affinities of compounds. The primary sulfonamides stand-out
among various inhibitors as ones that bind to CAs specifically and
significantly stronger than other reviewed compounds. Therefore,
in the search for the 3D (crystallographic complex) structure –
energetics correlations, the primary sulfonamides is the focus,
similarly to 2D (chemical structure) – energetics correlations
described in previous sections. In this section, all CA crystal struc-
tures available in the PDB that have sulfonamide compounds
bound and the intrinsic binding information is available, are
Fig. 28. Binding Gibbs energy contributions of compound functional groups in the search of fluorinated compounds that would selectively bind and inhibit CA IX.
The map shows a series of compounds connected by arrows beginning with benzenesulfonamide as the weakest inhibitor and ending with the best inhibitors on
the right. Numbers next to the structures show the intrinsic Gibbs energies of compound binding to each recombinant human CA isoform. Numbers at the arrows
show the differences between the affinities to two connected isoforms. Larger differences are depicted in larger font size to emphasize the largest energy gains
upon chemical modifications of the compounds.
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reviewed by listing the structures next to the intrinsic thermody-
namic parameters of binding. Such correlations may describe the
physical reasons behind the affinities and could lead to rational
design of compounds with desired binding properties to any pro-
tein target, not limited to CA. The goal is to search for correla-
tions that would be of general importance for any compound
interaction with its target protein.
Figures 1–9 in supplementary figures file show the Pymol ren-
derings of compounds bound to human CAs. The CA crystal
structures from the PDB are shown next to the compound chem-
ical structure together with the intrinsic binding data. Each figure
arranges the structures of inhibitors bound to one CA isoform.
The crystal structures are shown in the same orientation to visu-
alize the entrance of the compound. Hydrophobic residue surface
area is colored yellow, while the charged and polar amino acid
surface is blue.
The crystal structure–thermodynamic parameter correlations
show that the compounds span many orders of magnitude in
affinity, from mM to pM, and small structural changes may
lead to large changes in the binding energetics that are not fully
understood. It seems that not only the positions of each atom
at the protein–ligand interface are important, but probably also
the water molecules that are being displaced by the bound ligand
from the protein and ligand surface. All these contributions are
not clear and therefore it is not yet possible to predict the affini-
ties, enthalpies, and entropies from the structural arrangement of
the ligand and vice versa – the structural arrangement from the
thermodynamic parameters.
Quite a few observations and conclusions may be made based
on a comparison of compounds with similar chemical structure.
When a large collection of crystal structures confirms that all
studied primary sulfonamide compounds bind to CAs via a coor-
dination bond between the amino nitrogen and ZnII, we can draw
the structure–thermodynamics maps showing the functional
group contributions to the binding energies and extend the
maps to compounds whose crystal structures are not available.
Fig. 29. Comparison of the binding thermody-
namic parameters in structurally-related com-
pound pairs arranged according to the buried
and accessible surface areas (BSA + ASA) which
were calculated from the crystal structures as
described by Smirnov et al. (2018). Panels (a)
and (b) show the Gibbs energies of binding, (c)
and (d) the intrinsic enthalpies of binding, and
(e) and (f) – the entropies multiplied by the
absolute temperature. Panels on the left show
the pairs that are called similar, meaning that
the sulfonamide benzene ring is positioned
identically in both crystal structures, while the
panels on the right show dissimilar binders,
where the position of the benzene ring is differ-
ent in the pair. In the similar binders, there is a
significant loss of exothermic enthalpy observed
upon addition of a hydrophobic group on a
compound. However, in dissimilar binders, the
opposite tendency is observed – the enthalpy
is gained upon the addition of a hydrophobic
surface. The bottom two panels G and H show
the crystallographic positions of the similar (G)
and dissimilar (H) pairs of binders.
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The sulfonamide groups will always be oriented towards the ZnII
in the active site and the remaining tail part of the compound
would extend towards the entrance of the protein or bind to the
surface areas nearby which may differ in each isoform, being
hydrophobic or hydrophilic.
The development of compounds of VD series containing fluo-
rine atoms in the benzenesulfonamide ring that led to the discov-
ery of CA IX inhibitors of pM affinity and significant selectivity
over other CA isoforms is shown in Fig. 28. This compound com-
parison map shows the intrinsic Gibbs energies of binding to each
CA isoform and the differences in the energies between two adja-
cent compounds. The adjacent compounds in the map have small
structural differences that lead to energetic changes of binding. It
could be helpful to remember that the gain of −6 kJ mol−1 of
Gibbs energy is equivalent to a 10-fold gain in Kd. Starting with
benzenesulfonamide on the left upper corner of the map, it is
clear that this compound exhibits strong affinity towards CA IX
and is slightly selective over other isoforms. Addition of four fluo-
rines did not improve the intrinsic binding (though improved the
observed affinities). Further addition of para tail practically did
not have an effect on affinity towards CA IX. The main gain in
both the affinity and selectivity was achieved by an addition of
para or meta bulky substituents that were designed to bind in
the hydrophobic pocket on CA IX, based on the chimeric CA
IX structure (Dudutienė et al., 2014). Furthermore, the addition
of these substituents significantly diminished the binding of
these compounds to CA I, thus reducing an undesired side effect
in a possible anticancer therapy targeting CA IX.
Development of another series, the chlorinated EA com-
pounds towards CA XII is shown in Supplementary Fig. 11. At
the end of this series is a compound that exhibits subnanomolar
affinity and significant selectivity towards CA XII, another anti-
cancer target. The logic of the development is the same – the
search of functional groups that would selectively bind to the
desired isoform but would not bind as strongly to non-desired
isoforms.
The enthalpies of binding are still poorly understood, but they
should provide information on the contacts between the ligand
and protein. The larger negative exothermic enthalpy would indi-
cate that the compound makes better contacts with the protein
and the binding is more specific. Enthalpic development of high-
affinity CA IX inhibitors of VD series is shown in Supplementary
Fig. 12. The enthalpies of binding of the best compounds actually
were not the most exothermic. However, the dissection of
enthalpic and entropic contributions helped to provide the direc-
tions of compound design.
Correlations between the buried surface areas and the changes
in enthalpies and entropies of binding of several compounds are
shown in Fig. 29. The compounds were arranged in structurally
similar pairs where there is an increase in the hydrophobic surface
area when comparing them. In the case of similar binders, there
was a tendency to observe a less exothermic enthalpy change
and increased the entropy of binding. However, in the case of dis-
similar binders, there was an opposite tendency observed.
Significantly more data would be needed to ensure that such
observations are of general use for the rational design of ligands
that would bind the desired protein.
High-affinity and selective inhibitors of CA isoforms
One of the main practically-useful outcomes of this
structure-activity correlation study of CAs is a series of
Fig. 30. Several compounds that exhibit high affinity towards one CA isoform and significant selectivity over CA I and CA II. The observed and intrinsic Kds of the
compounds to the most important CAs are shown below.
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compounds that were designed and exhibited high affinity for one
CA isoform and thousand-fold selectivity over most or all remain-
ing human CA isoforms, especially CA I and CA II. The struc-
tures of five such compounds are shown in Fig. 30 together
with the observed Kds towards a particular CA isoform and com-
pared with the affinities for CA I and CA II. Note that here we
chose to list the observed affinities in addition to the intrinsic
ones because for a pharmaceutical developer of lead structures
it is important to know what is the potency/affinity of the com-
pound under physiological conditions such as pH 7.0. The affin-
ities of our best compounds towards CA I and CA IX reached
from 10 to 100 pM, while for CA IV, CA VA, and CA XII –
around 1nM. These compounds have a potential to be further
developed as pharmaceuticals.
Conclusions
In this paper, we have reviewed and provided our opinion on the
state-of-the-art in the design of small molecule inhibitors of
human CAs. Among the techniques that are most often used
and are of most importance in the experimental assessment of
compound interaction with CAs and inhibition of their enzymatic
activity are stopped-flow assay of the inhibition of CA enzymatic
activity, isothermal titration calorimetry, fluorescent thermal shift
assay, and SPR. Every one of these methods has advantages and
disadvantages and it is advised to obtain data by several orthogo-
nal techniques that complement each other and increase our
knowledge in various aspects of interaction. For example, FTSA
has the widest affinity range, SFA is the only method that directly
determines the inhibition of enzymatic activity, ITC is the only
method that directly determines the enthalpy of interaction, and
SPR is the only technique from this list that determines the kinetic
parameters of binding.
The interaction between the best-known inhibitors of CAs,
primary sulfonamides, is hindered by the binding-linked reac-
tions, such as deprotonation of the sulfonamide amino group
or protonation of the CA-Zn(II)-bound hydroxide. It seems
that in many cases a non-dominant form of the compound or
protein is binding and, therefore, the binding is strongly influ-
enced by buffer or pH. It is important to subtract all such
binding-linked reactions in order to obtain the intrinsic thermo-
dynamic and kinetic binding parameters. Such parameters are
necessary to obtain correlations between compound chemical
structures and binding efficiency. It is not fully correct to develop
compound structures based only on the observed binding
parameters.
The 85 X-ray crystallographic structures of 60 compounds
bound to six CA isoforms together with a database of 400 primary
sulfonamide compound binding to 12 recombinant human cata-
lytically active CAs provided insight in the chemical structural
features that strengthen compound binding and in some cases
make the compounds more selective towards a particular CA iso-
form that is a potential drug target. The data should also be of use
for computational modelers that build approaches to design novel
compounds in silico. Compounds that reached pM to nM affinity
towards CA I, CA IV, CA VA, CA IX, and CA XII and exhibited
thousands of fold selectivity towards these isoforms were pro-
posed as compounds suitable for further development as drugs
targeting these isoforms.
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